UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

☒   ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 20162017

or

   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

Commission File Number 000-11102

OCEAN BIO-CHEM, INC.

(Exact name of registrant as specified in its charter)

Florida 59-1564329

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

4041 SW 47 AVENUE

FORT LAUDERDALE, FLORIDA  33314

(Address of principal executive offices)

 

954-587-6280

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Name of each exchange on which registered
Common Stock, $0.01 par value The NASDAQ Stock Market

Securities registered pursuant to Section 12(g) of the Act:

None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Yes ☐  No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.  Yes  ☐   No ☒ 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  ☒   No  ☐ 

Indicate by check mark whether registrant has submitted electronically and posted on its corporate Web site, if any every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes ☒    No  ☐ 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  ☐ 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company or emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer”filer,” “smaller reporting company” and “smaller reporting“emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes  ☐   No  ☒ 

The aggregate market value of the Common Stock held by non-affiliates of the registrant at June 30, 20162017 was $7,071,550,$12,234,396, based upon the closing price of the registrant’s common stock on the NASDAQ Capital Market.  For purposes of making this computation only, all executive officers, directors and beneficial owners of more than five percent of the registrant'sregistrant’s Common Stock are deemed to be affiliates. 

At March 31, 2017, 9,146,93729, 2018, 9,254,580 shares of the registrant’s Common Stock were outstanding. 

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant'sregistrant’s definitive proxy statement, which will be filed not later than April 30, 2017,2018, are incorporated by reference in Part III of this report.

 

 

 

OCEAN BIO-CHEM, INC.

 

TABLE OF CONTENTS

 

  Page
Part I  
Item 1.Business1
Item 1A.Risk Factors4
Item 1B.Unresolved Staff Comments5
Item 2.Properties5
Item 3.Legal Proceedings5
Item 4Mine Safety Disclosures5
   
Part II  
Item 5.Market for Registrant’s Common Equity,  Related Stockholder Matters and Issuer Purchases of Equity Securities6
Item 6.Selected Financial Data6
Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations6
Item 7A.Quantitative and Qualitative Disclosures about Market Risk1011
Item 8.Financial Statements and Supplementary Data1011
Item 9.Changes in and Disagreements With Accountants on Accounting and Financial Disclosure1011
Item 9A.Controls and Procedures11
Item 9B.Other Information11
   
Part III  
Item 10.Directors, Executive Officers and Corporate Governance1112
Item 11.Executive Compensation1112
Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters1112
Item 13.Certain Relationships and Related Transactions, and Director Independence1112
Item 14.Principal Accounting Fees and Services1112
   
Part IV  
Item 15.Exhibits, Financial StatementsStatement Schedules1213

Item 16

Form 10-K Summary

1213

Signatures 13
Signatures14
Index To Consolidated Financial StatementsF-1

 

Forward-looking Statements:

 

Certain statements contained in this Annual Report on Form 10-K, including without limitation, the anticipated time of completion of the expansion of our manufacturing and warehouse facilities,facilities; our ability to locate substitute manufacturing facilities in the event arrangements with any third party manufacturer are discontinued,discontinued; our ability to renew or replace our revolving credit facility,facility; anticipated decreases in sellingrelocation of our fabrication and administrative expenses,assembly operations relating to brushes used for cleaning boats, automobiles and recreational vehicles; our ability to provide required capital to support inventory levels,levels; the effect of price increases in raw materials that are petroleum or chemical based or commodity chemicals on our margins,margins; and the sufficiency of funds provided through operations and existing sources of financing to satisfy our cash requirements constitute forward-looking statements.  For this purpose, any statements contained in this report that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the generality of the foregoing, words such as "believe," "may," "will," "expect," "anticipate," "intend,"“believe,” “may,” “will,” “expect,” “anticipate,” “intend,” or "could,"“could,” including the negative or other variations thereof or comparable terminology, are intended to identify forward-looking statements.  These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from those expressed or implied by such forward-looking statements.  Factors that may affect these results include, but are not limited to, unanticipated delays in completion of the expansion of our manufacturing and warehouse facilities; the highly competitive nature of our industry; reliance on certain key customers; changes in consumer demand for marine, recreational vehicle and automotive products; advertising and promotional efforts; exposure to market risks relating to changes in interest rates, foreign exchange rates, prices for raw materials that are petroleum or chemical based and other factors.factors discussed below under Item 1A, “Risk Factors.”

 

 

 

PART I

 

Item 1.  Business

 

General:

 

We are principally engaged in the manufacture, marketing and distribution of a broad line of appearance, performance and maintenance products for the marine, automotive, power sports, recreational vehicle and outdoor power equipment markets, under the Star brite® and Star Tron® brand names. We sell these products within the United States of America and Canada.  In addition, we produce private label formulations of many of our products for various customers and provide custom blending and packaging services for these and other products.  We also manufacture, market and distribute disinfectant, sanitizing and deodorizing products under the Performacide® and Star brite® brand names, utilizing a patented delivery system for use with products containing chlorine dioxide. Unless the context indicates otherwise, we sometimes refer to Ocean Bio-Chem, Inc. and its consolidated subsidiaries as “the Company," "we"” “we” or "our.“our.

 

Ocean Bio-Chem, Inc. was incorporated in 1973 under the laws of the state of Florida.  In 1981, we purchased, from Peter G. Dornau and Arthur Spector, the co-founders of the Company, rights to the Star brite® trademark and related products for the United States and Canada.  Mr. Dornau, our Chairman, President and Chief Executive Officer, has retained rights to these assets with respect to all other geographic areas.  Accordingly, products we manufacture that are sold outside of the United States and Canada are purchased from us and distributed by two companies owned by Mr. Dornau.  Net sales to the two companies in 20162017 and 20152016 totaled approximately $2,070,000 and $1,850,000 or 5.3% and $2,075,000 or 5.1% and 6.1% of our net sales, respectively.  See Note 9 to the consolidated financial statements included in this report for additional information.

 

Because our operations involve, in all material respects, substantially similar manufacturing and distribution processes, our operations constitute one reportable segment for financial reporting purposes.

 

Recent Developments:

 

We are proceeding withnearing completion of a project to expandinvolving expansion of the manufacturing, warehouse and distribution facilities of our subsidiary, Kinpak,KINPAK Inc. ("Kinpak"(“Kinpak”) in Montgomery, Alabama. As currently contemplated, the project will entailAlabama (the “Expansion Project”). The Expansion Project principally entails an approximately 85,000 square feet addition to the facilities and an expansion of Kinpak’s outdoor blended tank farm to accommodate an additional 500,000 gallons in tank capacity, thereby doubling the tank farm’s current capacity. The first phase ofaddition to the project, involvingfacilities and expansion of the tank farm was initiated earlier in 2017. We are using internal funds for this phase, although we currently are in negotiations to finance the costscompleted. The remaining parts of the entire project. Nevertheless,Expansion Project involve additional upgrades to warehouse facilities and installation of new manufacturing equipment. At December 31, 2017, expenditures in connection with the Expansion Project aggregated approximately $5.1 million, and we cannot assure that such financing will be obtained. We currently estimate that the projecttotal cost of the Expansion Project will be approximately $4.7$6.0 million. The Expansion Project is expected to be completed and placed into service during 2018. Most of the Expansion Project is being financed with the proceeds of an industrial development bond financing, described in Note 6 to the consolidated financial statements included in this report.

 

Products:

 

The products that we manufacture and market include the following:

 

Marine:  Our marine line consists of polishes, cleaners, protectants and waxes under the Star brite® brand name, enzyme fuel treatment under the Star Tron® brand name, and private label products sold by some of our customers.  The marine line also includes motor oils, boat washes, vinyl cleaners, protectants, teak cleaners, teak oils, bilge cleaners, hull cleaners, silicone sealants, polyurethane sealants, polysulfide sealants, gasket materials, lubricants, antifouling additives and anti-freeze coolants.  In addition, we manufacture a line of brushes, poles, tie-downs and other related marine accessories.

 

Automotive:  We manufacture a line of automotive products under the Star brite® and Star Tron® brand names  The automotive line includes fuel treatments for both gas and diesel engines, motor oils, greases and related items.  Our Star Tron® enzyme fuel treatment is designed to eliminate and prevent engine problems associated with fuel containing 10% ethanol (E-10 fuel) including, among other things, fuel degradation, debris in fuel (gum and varnish formation) and ethanol’s propensity to attract water (which can adversely affect octane). ItStar Tron® fuel treatment also increases fuel economy by cleaning the fuel delivery system and facilitating more complete and uniform combustion.  In addition, we produce anti-freeze and windshield washes under the Star brite® brand and under private labels for customers.  We also produce automotive polishes, cleaners and other appearance items.

1

 

Recreational Vehicle/Power Sports:  We market Star Tron® fuel treatment and other specialty products to the recreational vehicle market, including snow mobiles, all-terrain vehicles and motorcycles.  For power sports enthusiasts, Star Tron® provides a viable solution to a number of problems associated with E-10 fuel, which is fuel containing 10% ethanol.fuel.  Other specialty recreational vehicle/power sports products include cleaners, polishes, detergents, fabric cleaners and protectors,protectants, silicone sealants, waterproofers, gasket materials, degreasers, vinyl cleaners and protectors,protectants, toilet treatment fluids and anti-freeze/coolant.

 

Outdoor Power Equipment/ Lawn & Garden: We market Star Tron® as a solution to help rectify a number of operating engine problems associated with E-10 fuel in commercial lawn equipment and other home and garden power equipment.

1

 

Disinfectants, Sanitizers and Deodorizers: Our line of disinfectant, sanitizing and deodorizing products are marketed under the Performacide®and Star brite® brand names. Performacide® products include disinfectants for hard, non-porous surfaces, air care products for deodorizing and products to eliminate mold and mildew. The U.S. Environmental Protection Agency has accepted labeling for Performacide® used in hard surface applications that claims, among other things, effectiveness as a virucide against a variety of viruses, including HIV-1, Influenza-A, Herpes Simplex-2, Poliovirus-1 norovirus and rotavirus; as a disinfectant against a number of different types of bacteria; and as a sanitizer against certain types of bacteria that cause food borne illnesses. We are directing distribution efforts principally towards the marine, automotive, and home restoration, law enforcement and agriculture markets, and to institutions such as schools and to travel and leisure facilities such as hotels and cruise ships.schools.

 

Contract Filling and Blow Molded Bottles:  We blend and package a variety of chemical formulations to our customers’ specifications.  In addition, we manufacture for sale to various customers assorted styles of both PVC and HDPE blow molded bottles.

 

Manufacturing:  We produce the majority of our products at Kinpak’s manufacturing facilities in Montgomery, Alabama.  In addition, we contract with various third party manufacturers to manufacture some of our products, which are manufactured to our specifications using our provided formulas.  Each third party manufacturer enters into a confidentiality agreement with us.

 

We purchase raw materials from a variety of suppliers; all raw materials used in manufacturing are readily available from alternative sources.  We design our own packaging and supply our outside manufacturers with the appropriate design or packaging.  We believe that our internal manufacturing capacity and our arrangements with our current outside manufacturers are adequate for our present needs.

 

In the event that arrangements with any third party manufacturer are discontinued, we believe that we will be able to locate substitute manufacturing facilities without a substantial adverse effect on our manufacturing and distribution.

 

Marketing and Significant Customers: Our branded and private label products are sold through national retailers such as Wal-Mart, Tractor Supply, West Marine and Bass Pro Shops.  Additionally, we market our products via online retailers.  We also sell to national and regional distributors that resell our products to specialized retail outlets.  In the case of Performacide® disinfectant/sanitizing products, we sell to distributors that resell our products, in some cases under private labels, to end users principally in the marine, automotive, home restoration, automotive, law enforcement and agriculture markets.

 

Net sales to each of two customers exceeded 10% of our consolidated net sales, and in the aggregate constituted approximately 34.0% and 33.0% and 38.2% of our consolidated net sales for the years ended December 31, 20162017 and 2015,2016, respectively.  Net sales to our five largest unaffiliated customers for the years ended December 31, 20162017 and 20152016 amounted to approximately 48.8%52.2% and 49.0%48.8% of our consolidated net sales, respectively, and at December 31, 20162017 and 2015,2016, outstanding accounts receivable balances from our five largest unaffiliated customers aggregated approximately 36.0%50.9% and 39.4%36.0% of our consolidated accounts receivable, respectively.

 

We market our products through both internal salesmen and external sales representatives who work on an independent contractor commission basis.  Our personnel also participate in sales presentations and trade shows.  In addition, we market our brands and products through advertising campaigns in national magazines, on television, on the internet, in newspapers and through product catalogs.  Our products are distributed primarily from Kinpak’s manufacturing and distribution facility in Montgomery, Alabama.  Since 2008, we have participated in a vendor managed inventory program with one major customer. See Note 2 to the consolidated financial statements included in this report for additional information.

 

Backlog, seasonality, and selling terms: We had no significant backlog of orders at December 31, 2016.2017.  We generally do not give customers the right to return products.  The majority of our products is non-seasonal and is sold throughout the year.  Normal trade terms offered to credit customers range from 30 to 180 days depending on the nature of the customer.days.  However, at times we offer extended payment terms or discount arrangements as purchasing incentives to customers.  TheseHistorically, these initiatives dohave not materially affect customaryaffected our overall profit margins.

 

Competition:

 

Competition with respect to our principal product lines is described below.  The principal elements of competition affecting all of our product lines are brand recognition, price, service and the ability to deliver products on a timely basis.

 

Marine:  We have several national and regional competitors in the marine marketplace.  We do not believe that any competitor or small group of competitors hold a dominant market share.  We believe that we can increase or maintain our market share through expenditures directed to our present advertising and distribution channels.

2

 

Automotive:  There are a large number of companies, both national and regional, that compete with us.  Many are more established and have greater financial resources than we do.  While our market share is small, the total market size is substantial.  We believe that we have established a reasonable market share through our present advertising and distribution channels, considering the large size of this market.

 

Recreational Vehicle/Power Sports:  We compete with national and regional competitors.  We do not believe that any competitor or small group of competitors hold a dominant market share.  We believe that we can increase or maintain our market share by utilizing similar advertising and distribution channels similar to those we use in the marine market.

 

2

Outdoor Power Equipment/Lawn & Garden:  We compete with several established national and regional competitors.  We do not believe that any competitor or small group of competitors hold a dominant market share.  We have attempted to make inroads in this market by emphasizing Star Tron®Tron®’s unique formulation and by increasing our advertising and attendance at trade shows.

 

Disinfectants, Sanitizers and Deodorants: There are a large number of companies that compete with us, many of which are much larger, and have much greater financial resources than we do. We emphasize the effectiveness of chlorine dioxide, coupled with the convenience in application of our Performacide®products.

 

Trademarks:  We have obtained registered trademarks for Star brite®, Star Tron®, Performacide®and other trade names used on our products.  We view our trademarks as significant assets because they provide product recognition.  We believe that our intellectual property is protected,trademarks provide protection in the geographic markets we serve, but we cannot assure that our intellectual property rights can be successfully asserted in the future or will not be invalidated, circumvented or challenged. 

 

Patents:  We own several patents, the most significant of which relate to a delivery system for use with products containing chlorine dioxide (the “ClO2Patents”).  The ClO2 patents expire in 2022.  We have encountered difficulty in protecting the ClO2patents through litigation.  See “Risk Factors - If we do not utilize or successfully assert intellectual property rights, our competitiveness could be materially adversely affected,” in Item 1A of this report for additional information.  A 2014 adverse judgment in patent litigation that was upheld on appeal in 2015 has limited the scope of protection provided by the patent.  To date, we do not believe the judgment has materially impaired our ability to effectively market and distribute our Performacide®products.  However, we are unable to predict the long-term competitive effect of the judgment on these products. 

 

New Product Development:  We continue to develop specialized products for the marine, automotive, recreational vehicle/power sports and outdoor power equipment/lawn and garden markets.  Expenditures for new product development have not been significant and are charged to operations in the year incurred.

 

Personnel:  At December 31, 2016,2017, we had 128140 full-time employees.employees and two part-time employees who constituted one full-time equivalent.  The following table provides information regarding personnel working for the Company and its subsidiaries at December 31, 2016:2017:

 

Location Description Full-timeNumber of Employees 
Fort Lauderdale, Florida Administrative, sales, and marketing  4144 
Fort Lauderdale, Florida Manufacturing and distribution  56 
Montgomery, Alabama Manufacturing and distribution  8292*
     128142 

 

* Includes two part-time employees, who constitute one full-time equivalent.

 3 

 

 

Item 1A.  Risk Factors

 

If we do not compete effectively, our business will suffer.

 

We confront aggressive competition in the sale of our products.  In each of the markets in which we sell our products, we compete with a number of national and regional competitors.  Competition in the automotive market is particularly intense, with many national and regional companies marketing competitive products.  Many of our competitors in the automotive market are more established and have greater financial resources than we do.  Moreover, we confront intense competition with respect to our Performacide® disinfectant, sanitizing and deodorizing products from a large number of competitors, many of which are well established and have substantially greater financial resources than we do. Our inability to successfully compete in our principal markets would have a material adverse effect on our financial condition, results of operations and cash flows.

 

Our business is, to a significant extent, dependent on a small number of major customers, and the loss of any of these customers could adversely affect our financial condition, results of operations and cash flows.

Net sales to our five largest unaffiliated customers accounted for 52.2% of our consolidated net sales in 2017; the two largest unaffiliated customers accounted for 34.0% of our consolidated net sales in 2017. The loss of any of these customers would have a material adverse effect on our financial condition, results of operations and cash flows.

Our Chairman, President and Chief Executive Officer is a majority shareholder who controls us, and his interests may conflict with or differ from the Company’s interests.

Peter G. Dornau, our Chairman, President and Chief Executive Officer, together with a family entity he controls, owns approximately 51.4% of our Common Stock.  As a result, Mr. Dornau has the power to elect all of our directors and effectively has the ability to prevent any transaction that requires the approval of our Board of Directors and our shareholders.   Products that we manufacture and that are sold outside of the United States and Canada are purchased from us and distributed by two companies owned by Mr. Dornau, which we refer to as the “affiliated companies.”  The affiliated companies also collectively own the rights to the Star brite® and Star Tron® trademarks and related products outside of the United States and Canada. Sales to the affiliated companies aggregated approximately $2,070,000 and $1,850,000 during the years ended December 31, 2017 and 2016, respectively.  In addition, we provided administrative services to the affiliated companies for fees aggregating approximately $884,000 and $735,000 (including $120,000 and $115,000 to reimburse the Company for business related expenditures that we made on behalf of the affiliated companies) during the years ended December 31, 2017 and 2016, respectively.  Receivables due from the affiliated companies in connection with product sales and administrative services totaled approximately $1,584,000 and $1,190,000 at December 31, 2017 and 2016, respectively. The accounts receivable turnover ratio for the year ended December 31, 2017 with respect to sales to the affiliated companies was approximately 3.3 and with respect to administrative services was approximately 1.1. Management believes that the sales and provision of administrative services to the affiliated companies do not involve more than normal credit risk.

We have entered into other transactions with entities owned by Mr. Dornau.  See Notes 9 and 10 to the consolidated financial statements included in this report for additional information.

Economic conditions can adversely affect our business.

 

We are subject to risks arising from adverse changes in general domestic and global economic conditions, including recession or economic slowdown and disruption of credit markets, which may impair the ability of our customers to satisfy obligations due to us.  In addition, we believe that adverse economic conditions in recent years adversely constrained discretionary spending, which we believe has, at times, adversely affected our product lines, particularly those directed to the marine and recreational vehicle markets.  AWhile published reports indicate that economic conditions recently have improved both domestically and globally, a future decline in economic conditions could have a material adverse effect on our financial condition, results of operations and cash flows.

 

If we do not effectively utilize or successfully assert intellectual property rights, our competitivenesscompetiveness could be materially adversely affected.

 

We rely on trademarks and trade names in connection with our products, the most significant of which are Star brite® and Star Tron®.  In addition, we own patents we have viewed as providing some degree of competitive support for our Performacide® products. We rely on trademark, trade secret, patent and copyright laws to protect our intellectual property rights.  We cannot assure that these intellectual property rights will be effectively utilized or, if necessary, successfully asserted.  There is a risk that we will not be able to obtain and perfect our own intellectual property rights, or, where appropriate, license from others intellectual property rights necessary to support new product introductions.  Our intellectual property rights, and any additional rights we may obtain in the future, may be invalidated, circumvented or challenged in the future, and the legal costs necessary to protect our intellectual property rights could be significant.  In this regard, in 2013, we filed a patent infringement lawsuit in the United States District Court for the Southern District of Florida with respect to a U.S. patent relating to a delivery system for use with products containing chlorine dioxide, but the District Court granted the defendants'defendants’ motion for summary judgment, which the Federal Circuit Court of Appeals affirmed in January 2015. As a result, in March 2015, we stipulated to the dismissal with prejudice of our patent infringement claims in another lawsuit related to the same patent, and, in response, the court dismissed our claims. We are unable to predict the long-term competitive effect of the adverse outcome in the patent litigation on our Performacide®products. Our failure to perfect or successfully assert intellectual property rights could harm our competitive position and could have a material adverse effect on our financial condition, results of operations and cash flows.

4

 

Environmental matters may cause potential liability risks.

 

We must comply with various environmental laws and regulations in connection with our operations, including those relating to the handling and disposal of hazardous wastes and the remediation of contamination associated with the use and disposal of hazardous substances.  A release of such substances due to accident or intentional act could result in substantial liability to governmental authorities or to third parties.  In addition, we are subject to reporting requirements with respect to certain materials we use in our manufacturing operations.  In January 2011, Kinpak, which owns our manufacturing facility in Montgomery, Alabama, became subject to a consent agreement and final order with the United States Environmental Protection Agency relating to its alleged failure to complete and submit certain required forms with respect to toxic and hazardous chemicals used at its facilities.  Under the consent agreement and final order, Kinpak paid a civil penalty of $110,000.  It is possible that we could become subject to additional environmental liabilities in the future that could have a material adverse effect on our business, financial condition, results of operations and cash flows.

 

Our variable rate indebtedness exposes us to risks related to interest rate fluctuation and matures in August 2017.2018.

 

We have a revolving line of credit with a variable interest rate.  Interest on the revolving line of credit is payable at the 30 dayone month LIBOR rate plus 1.50% per annum, computed on a 365/360 basis. During the year endedAt December 31, 2016, we did not utilize the revolving line of credit, and at December 31, 2016,2017, we did not have any borrowings outstanding under the revolving line of credit.   However, if we borrow amounts under the revolving line of credit in the future, and if interest rates were to increase significantly, our financial condition, results of operations and cash flows could be materially adversely affected. Moreover, we believe, but cannot assure, that we could obtain a renewal of the revolving line of credit or a suitable replacement facility when the current facility terminates in August 2017.2018. Our failure to renew or obtain a replacement for our current facility may impair our financial flexibility and have a material adverse effect on our business.

4

Our Chairman, President and Chief Executive Officer is a majority shareholder who controls us, and his interest may conflict with or differ from the Company's interests.

Peter G. Dornau, our Chairman, President and Chief Executive Officer, together with a family entity he controls, owns approximately 51.9% of our Common Stock.  As a result, Mr. Dornau has the power to elect all of our directors and effectively has the ability to prevent any transaction that requires the approval of our Board of Directors and our shareholders.   Products that we manufacture and that are sold outside of the United States and Canada are purchased from us and distributed by two companies owned by Mr. Dornau, which we refer to as the “affiliated companies.”  Sales to the affiliated companies aggregated approximately $1,850,000 and $2,075,000 during the years ended December 31, 2016 and 2015, respectively.  An affiliated company owns the rights to the Star brite® and Star Tron® trademarks and related products outside of the United States and Canada.

In addition, we provided administrative services to the affiliated companies for fees aggregating approximately $621,000 and $527,000 during the years ended December 31, 2016 and 2015, respectively.  While the terms of the sales to the affiliated companies differed from the terms of sale to other customers, the affiliated companies bear their own warehousing, distribution, advertising, selling and marketing costs, as well as their own freight charges (we pay freight charges in connection with sales to our domestic customers on all but small orders).  Moreover, we do not pay sales commissions with respect to products sold to the affiliated companies.  As a result, we believe our profit margins with respect to sales of our products to the affiliated companies are similar to the profit margins we realize with respect to sales of the same products to our larger domestic customers.  Management believes that the sales to the affiliated companies do not involve more than normal credit risk or present other unfavorable features.  We have entered into other transactions with entities owned by Mr. Dornau.  See Notes 9 and 10 to the consolidated financial statements included in this report for additional information

 

Trading in our Common Stock has been limited, and our stock price could potentially be subject to substantial fluctuations.

 

Our common stock is listed on the NASDAQ Capital Market, but trading in our stock has been limited.  Our stock price could be affected substantially by a relatively modest volume of transactions.

 

Item 1B. Unresolved Staff Comments

 

Not applicable.

 

Item 2. Properties

 

Our executive offices and one of our manufacturing facilities are located in Fort Lauderdale, Florida and are leased from an entity controlled by our Chairman, President and Chief Executive Officer.  The lease covers approximately 12,700 square feet of office, manufacturing, and warehouse space.  The lease expires in December 2023. See Note 10 to the consolidated financial statements included in this report for additional information.

 

We own Kinpak’sKinpak leases its Alabama manufacturing facility, whichfacilities from The Industrial Development Board of the City of Montgomery, Alabama (the “IDB”). Kinpak entered into the lease in its current form in connection with an industrial development bond financing related to the Expansion Project; Kinpak’s lease payments are used to fund repayment of the IDB’s obligations under the bond it issued in connection with the industrial development bond financing. See Note 6 to the consolidated financial statements included in this report for additional information. Under the lease, prior to the maturity date of the bond, Kinpak may repurchase the facilities for $1,000 if the bond has been redeemed or fully paid. The facilities currently contains(without giving effect to the Expansion Project) contain approximately 187,000 square feet of office, plant and warehouse space on 20 acres of land. The facility also includes a 500,000 gallon outdoor blending tank farm.  As discussed above in Item 1, Recent Developments, we are nearing completion of the Expansion Project.

 

In addition, we lease a 15,000 square foot warehouse in Montgomery, Alabama, near the Kinpak manufacturing facility. We use the warehouse to fabricate and assemble brushes used for cleaning boats, automobiles and recreational vehicles. The lease expires in July 2018.  

We are proceedingplan to relocate the fabrication and assembly operations with an expansion project relatingrespect to Kinpak’sthe brushes to the expanded Kinpak manufacturing and warehouse facilities. See “Business – Recent Developments” in Item 1facilities prior to expiration of this report for additional information.the lease.

 

Item 3. Legal Proceedings

 

Not applicable

 

Item 4.  Mine Safety Disclosures

 

Not applicable.

 

 5 

 

 

PART II

 

Item 5.    Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 

Our common stock is traded on the NASDAQ Capital Market under the symbol OBCI.  A summary of the high and low sales prices during each quarter of 20162017 and 20152016 is presented below.

 

 1stQtr. 2ndQtr. 3rdQtr. 4thQtr. 
         
2017 High $5.15  $5.65  $5.47  $5.71 
 1stQtr. 2ndQtr. 3rdQtr. 4thQtr.  Low $3.66  $3.69  $3.51  $3.98 
                         
2016 High $2.66  $2.57  $3.17  $4.35  High $2.66  $2.57  $3.17  $4.35 
 Low $1.93  $2.08  $2.02  $2.61  Low $1.93  $2.08  $2.02  $2.61 
                  
2015 High $5.56  $4.45  $3.79  $3.19 
 Low $3.76  $3.33  $2.44  $2.02 

 

On December 31, 2016,2017, there were 116112 holders of record and approximately 1,200 beneficial ownersrecord. Because many of our common stock.shares are held by brokers and institutions on behalf of shareholders, we are unable to estimate the total number of shareholders represented by these record holders.

On April 13, 2017, the Board of Directors of Ocean Bio-Chem, Inc. declared a special dividend of $0.06 per share payable on May 11, 2017 to shareholders of record on April 27, 2017.  

 

On March 25, 2016, the Board of Directors of Ocean Bio-Chem, Inc. declared a special dividend of $0.06 per share payable on April 26, 2016 to shareholders of record on April 12, 2016. The Company did not pay any dividends in 2015.

Payment of dividends in the future will be subject to the discretion of the Board of Directors in light of numerous factors, including the Company'sCompany’s business performance and operating plans, capital commitments, liquidity and other factors.

  

Item 6.   Selected Financial Data

 

Not applicable.

 

Item 7.    Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion should be read in conjunction with our consolidated financial statements contained in Item 8 of this report.

 

Overview:

 

We are engaged in the manufacture, marketing and distribution of a broad line of appearance, performance, and maintenance products for the marine, automotive, power sports, recreational vehicle and outdoor power equipment markets, under the Star brite® and other trademarks within the United States and Canada. In addition, we produce private label formulations of many of our products for various customers and provide custom blending and packaging services for these and other products.  We also manufacture, market and distribute a line of products including disinfectants, sanitizers and deodorizers. We sell our products through national retailers and to national and regional distributors. In addition, we sell products to two companies affiliated with Peter G. Dornau, our Chairman, President and Chief Executive Officer; these companies distribute the products outside of the United States and Canada.

Transactions with the affiliated companies were made in the ordinary course of business. While the terms of thebusiness, and management believes that sales to the affiliated companies differed from the terms of sale to other customers, the affiliated companies bear their own warehousing, distribution, advertising, selling and marketing costs, as well as their own freight charges (the Company pays freight charges in connection with sales to its domestic customers on all but small orders).  Moreover, the Company does not pay sales commissions with respect to products sold to the affiliated companies.  As a result, the Company believes its profit margins with respect to sales of its products to the affiliated companies are similar to the profit margins it realizes with respect to sales of the same products to its larger domestic customers. Management believes that the sales to the affiliated companies diddo not involve more than normal credit risk or present other unfavorable features.risk.

 

We have commenced anare nearing completion of the Expansion Project, which involves the expansion of Kinpak’s manufacturing and warehouse facilities in Montgomery, Alabama. See “Business - Recent Developments” in Item 1 of this report.report for additional information.

The Tax Cuts and Jobs Act, which was enacted on December 22, 2017, changes United States tax law significantly. The most important change affecting Ocean Bio-Chem, Inc. is the reduction in the United States corporate income tax rate from 35% to 21%, effective January 1, 2018. Among other things, the reduction in the corporate tax rate resulted in a substantial decrease in our deferred tax liabilities, which is discussed in more detail below under “Results of Operations – Provision for income taxes.”

6

 

Our operating results for 2016 and 2015 were adversely affected by professional fees and expenses related to litigation against a competitor in which we and the competitor each claimed that the other was engaged in false advertising and related violations of law (the “Advertising Litigation”). Following a trial in which it was determined that neither party was liable to the other, the Advertising Litigation was concluded. Our professional fees and expenses related to the Advertising Litigation were approximately $1,146,000 in 2016. As the Advertising Litigation was concluded in 2016, and $1,174,000 in 2015.we had no expenses related to the Advertising Litigation during 2017.

 

Critical accounting estimates:

 

The preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates and assumptions.

 

We have identified the following as critical accounting estimates, which are defined as those that are reflective of significant judgments and uncertainties, are the most pervasive and important to the presentation of our financial condition and results of operations and, if subject to different assumptions and conditions, could lead to materially different results.

 

6

Revenue recognition and collectabilityCollectability of trade accounts receivable

 

Revenue from product sales is recognized when persuasive evidence of a contract exists, the sales price is fixed and determinable, the title of goods pass to the customer, and collectability of the related receivable is probable.  With respect to a customer for whom the Company manages the inventory at the customer's location, revenue is recognized when the products are sold to a third party.  In the ordinary course of business, we grant non-interest bearing trade credit to our unaffiliated customers on normal credit terms.terms that range from 30 to 180 days.  In an effort to reduce our credit risk, we perform ongoing credit evaluations of our customers and adjust credit limits based upon payment history and aging of receivables, as well as our customers’ creditworthiness, as determined by our review of their current credit information.  We monitor collections and payments from our customers and maintain a provision for estimated credit losses based upon our historical experience, specific customer collection issues and reviews of agings of trade receivables based on contractual terms.  We generally do not require collateral on trade accounts receivable.  We maintain an allowance for doubtful accounts based on our historical collection experience and expected collectability of the trade accounts receivable, after considering our historical collection experience, the period the trade accounts receivable arelength of time an account is outstanding, the financial position of the customer if known and information provided by credit rating services.   The adequacy of this allowance is reviewed each reporting period and adjusted as necessary.  Our allowance for doubtful accounts was approximately $75,000$79,000 and $78,000$75,000 at December 31, 20162017 and 2015,2016, respectively, which was approximately 1.6% and 1.5% of gross accounts receivable at December 31, 2017 and 2016, and 2015.respectively.  If the financial condition of our customers were to deteriorate, resulting in increased uncertainty as to their ability to make payments, or if unexpected events or significant future changes in trends were to occur, we may be required to increase the allowance.allowance or incur a bad debt expense. In this regard, we incurred a bad debt expense of approximately $199,000 in 2017, most of which resulted from a customer’s bankruptcy.

 

Inventories

 

InventoriesOur inventories primarily are composed of raw materials and finished goods and are stated at the lower of cost or market,net realizable value, using the first-in, first-out method.  Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. We maintain a reserve for slow moving and obsolete inventory to reflect the diminution in value resulting from product obsolescence, damage or other issues affecting marketability in an amount equal to the difference between the cost of the inventory and its estimated marketnet realizable value.  The adequacy of this reserve is reviewed each reporting period and adjusted as necessary.  We regularly compare inventory quantities on hand against historical usage or forecasts related to specific items in order to evaluate obsolescence and excessive quantities.  In assessing historical usage, we also qualitatively assess business trends to evaluate the reasonableness of using historical information as an estimate of future usage.  

 

Our slow moving and obsolete inventory reserve was $268,159$274,295 and $279,882$268,159 at December 31, 20162017 and 2015,2016, respectively.

 

Income taxes

 

IncomeWe account for income taxes are accounted for under the asset and liability method.  Under this method, deferred tax assets and liabilities are recognized to reflect the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured and recorded using currently enacted tax rates, which we expect will apply to taxable income in the years in which the differences between the financial statement carrying amounts of existing assets and liabilities and their tax bases are recovered or settled.  The differences are attributable to differing methods of financial statement and income tax treatment with respect to depreciation and reserves for trade accounts receivable and inventories. The likelihood of a material change in our expected realization of deferred tax assets is dependent on, among other factors, changes in tax law, future taxable income and settlements with tax authorities.  In this regard, the enactment of the Tax Cuts and Jobs Act resulted in a meaningful reduction in our net deferred tax liability as of December 31, 2017, reflecting the Tax Cuts and Jobs Act’s reduction of the United States corporate income tax rate. While management believes that its judgments and interpretations regarding income taxes are appropriate, significant differences in actual experience may require future adjustments to our tax assets and liabilities, which could be material.

 

In assessing the realizability of our deferred tax assets, we evaluate positive and negative evidence and use judgments regarding past and future events, including operating results and available tax planning strategies that could be implemented to realize the deferred tax assets.  Based on this assessment,We record a valuation allowance when necessary to reduce our deferred tax assets to the net amount that we determine when itbelieve is more likely than not that all or some portion of our deferredto be realized. We consider available evidence, both positive and negative, and use judgments regarding past and future events, including operating results and available tax assets may not be realized,planning strategies, in which case we would applyassessing the need for a valuation allowance, in an amount equal to future tax benefits that may not be realized, to offset our deferred tax assets.  We currently do not apply a valuation allowance to our deferred tax assets.  However, if facts and circumstances change in the future, a valuation allowance may be required.allowance.

7

 

Significant judgment is required in determining income tax provisions and in evaluating tax positions.  We establish additional provisions for income taxes when, despite the belief that tax positions are fully supportable, there remain certain positions that do not meet the minimum probability threshold, which is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority.  In the normal course of business, we and our subsidiaries are examined by various federal and state tax authorities.  We regularly assess the potential outcomes of these examinations and any future examinations for the current or prior years in determining the adequacy of our provision for income taxes.  We adjust the income tax provision, the current tax liability and deferred taxes in any period in which we become aware of facts that necessitate such an adjustment.  The ultimate outcomes of the examinations of our income tax returns could result in increases or decreases to our recorded tax liabilities, which would affect our financial results.

 

7

Intangible Assets

 

Intangible assets are acquired assets that lack physical substance and that meet specified criteria for recognition apart from goodwill. Our intangible assets include trademarks, tradenames, patents and royalty rights. We own several trademarks and trade names, including Star brite®, and Performacide®. We have determined that these intangible assets have indefinite lives and, therefore, are not amortized. In addition, we own several patents, the most significant of which are the ClO2 Patents, which relate to a device for producing chlorine dioxide that is incorporated in our deodorizer, sanitizer and disinfectant products. We amortize our patents over their remaining life on a straight line basis; amortization expense related to these the ClO2patents was approximately $51,000$52,000 ($51,000 for ClO2patents and $1,000 for other patents) for each of the years ended December 31, 20162017 and 2015.2016. In 2013, we acquired royalty rights relating to sales of products encompassing the ClO2 Patents’ technology (we purchased these rights from an unaffiliated entity that previously owned the ClO2 Patents and retained the royalty rights after selling the patents). We are amortizing the royalty rights over their remaining life on a straight line basis; amortization expense relating to the royalty rights was approximately $18,000 for each of the years ended December 31, 20162017 and 2015.2016. See Note 7 to the consolidated financial statements included in this report for additional information.

 

We evaluate our indefinite-lived intangible assets (trademarks and trade names) for impairment annually and at other times if events or changes in circumstances indicate that an impairment may have occurred. In evaluating our indefinite-lived intangible assets for impairment, we assess qualitative factors to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying value. If, after completing the qualitative assessment, we determine it is more likely than not that the fair value of the indefinite-lived intangible asset is greater than its carrying amount, the asset is not impaired. If we conclude it is more likely than not that the fair value of the indefinite-lived intangible assets is less than the carrying value, we would then proceed to a quantitative impairment test, which consists of a comparison of the fair value of the intangible assets to their carrying amounts. In 2016,2017, we performed a qualitative assessment on all of our indefinite lived assets and determined, based on the assessment, that their fair values were more likely than not higher than their carrying values.

 

We assess the remaining useful life and recoverability of intangible assets having finite lives (patents and royalty rights) whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Such events or circumstances may include, for example, the occurrence of an adverse change with respect to a product line that utilizes the intangible assets. Significant judgments in this area involve determining whether such an event or circumstance has occurred. Any impairment loss, if indicated, equals the amount by which the carrying amount of the asset exceeds the estimated fair value of the asset.

 

Results of Operations:

 

The following table provides a summary of our financial results for the years ended December 31, 20162017 and 2015:2016:

 

 For The Years Ended December 31,  For The Years Ended December 31, 
     Percent Percentage of Net Sales      Percent Percentage of Net Sales 
 2016 2015 Change 2016 2015  2017 2016 Change 2017 2016 
Net sales $36,205,444  $33,987,487   6.5%  100.0%  100.0% $38,933,458  $36,205,444   7.5%  100.0%  100.0%
Cost of goods sold  22,331,761   22,647,516   (1.4)%  61.7%  66.6%  24,436,780   22,331,761   9.4%  62.8%  61.7%
Gross profit  13,873,683   11,339,971   22.3%  38.3%  33.4%  14,496,678   13,873,683   4.5%  37.2%  38.3%
Advertising and promotion  3,117,164   3,010,758   3.5%  8.6%  8.9%  3,523,710   3,117,164   13.0%  9.1%  8.6%
Selling and administrative  7,660,377   7,579,682   1.1%  21.2%  22.3%  7,297,538   7,660,377   (4.7)%  18.7%  21.2%
Operating income  3,096,142   749,531   313.1%  8.6%  2.2%  3,675,430   3,096,142   18.7%  9.4%  8.6%
Interest (expense), net  (17,820)  (33,639)  (47.0)%  0.0%  0.1%
Other (expense)  ---   (12,522)  N/A   0.0%  0.0%
Interest income (expense), net  2,065   (17,820)  (111.6)%  0.0%  0.0%
Provision for income taxes  (983,151)  (242,676)  305.1%  2.7%  0.7%  (1,073,961)  (983,151)  9.2%  2.8%  2.7%
Net income $2,095,171  $460,694   354.8%  5.8%  1.4% $2,603,534  $2,095,171   24.3%  6.7%  5.8%

  

 8 

 

 

Net sales for the year ended December 31, 20162017 increased by approximately $2,218,000$2,728,000 or 6.5%7.5%, as compared to the year ended December 31, 2015.2016. The net sales increase principally is a result of increasedattributable to sales of Star brite® brandedour marine products to both retailers and wholesale distributorstwo of our products. In particular, we believe that the increased sales reflect the benefit of the inclusion of our products in more of our large national “brick and mortar” retail chain customers’ locations, as well as the provision of increased shelf space for our products by theselargest customers. In addition, ourwe experienced sales growth generally with respect to a wide range of customers, including mass merchandisers, large home improvement and marine/sports retail chains, and online retailers also increased as a result of higher consumer demand.

retailers.

 

Cost of goods sold indecreasedcreased by approximately $316,000$2,105,000 or 1.4%9.4% in 2016,2017, as compared to 2015.2016. The decreaseincrease in cost of goods sold despite the increase in net sales reflects the more favorable product mix resulting fromis principally a result of increased sales of Star brite® branded marine products.volume, higher raw material costs on our winterizing products and higher manufacturing costs.

 

Gross profit increased by approximately $2,534,000$623,000 or 22.3%4.5% during 2016,2017, as compared to 2015.2016. As a percentage of net sales, gross profit increaseddecreased to 37.2% in 2017 from 38.3% in 2016 from 33.4% in 2015.2016. The increasesincrease in gross profit andin 2017 is primarily attributable to increased sales volume. The decrease in gross profit as a percentage of net sales during 2017 is principally a result of the more favorable product mix discussed above.lower profit margins on sales of our winterizing products due to both lower sales prices and higher raw material costs.   

 

Advertising and promotion expenseincreased by approximately $106,000$407,000 or 3.5%13.0% during 2016,2017, as compared to 2015.2016.  As a percentage of net sales, advertising and promotion expense decreasedincreased to 9.1% in 2017 compared to 8.6% in 2016 compared to 8.9% in 2015.2016.  The gross increase in advertising and promotion expense is primarily a result of a $176,000 increaseincreases in customer cooperative advertising partially offset by a $66,000 decrease inallowances provided to select customers and other marketing expenses.

 

Selling and administrative expenses increaseddecreased by approximately $81,000$363,000 or 1.1%4.7%, during 2016,2017, as compared to 2015, reflecting an increase2016. The decrease reflects the conclusion of the Advertising Litigation in noncash stock based compensation expense of approximately $131,000. This increase was partially offset by a decrease of approximately $28,000 in2016. In 2016, legal fees and expenses related to the Advertising Litigation; such fees and expensesLitigation were approximately $1,146,000$1,146,000. This decrease was partially offset by increased employee compensation expenses (including salaries, commissions and $1,174,000 during 2016stock awards); bad debt expense of approximately $199,000, of which approximately $188,000 resulted from a customer’s bankruptcy; and 2015, respectively.  The Company expects sellingincreased costs of computer programming and administrative expenses to decline substantially in 2017 as a result of the conclusion of the Advertising Litigation during 2016.other information technology services. As a percentage of net sales, selling and administrative expenses decreased to 21.218.7 % in 20162017 from 22.3%21.2% in 2015.2016.

 

Interest income, net for the year ended December 31, 2017 was approximately $2,000; for the year ended December 31, 2016, interest expense, net decreased was approximately $18,000. Interest income in 2017 was generated principally by approximately $16,000 or 47.0%an escrow account in 2016, as comparedwhich a portion of the funds relating to 2015.an industrial development bond financing were deposited pending our utilization of such funds in connection with the Expansion Project. The decrease reflectsinterest income was offset principally by interest under an earlier term loan that matured on July 6, 2017; we paid all remaining principal and interest on the declining principal outstanding undermaturity date. The term loan also was the source of our term loan.primary interest obligation in 2016.

 

Provision for income taxes – Our provisionincreased by approximately $91,000 for income taxes for 2016 was approximately $983,000,the year ended December 31, 2017, or 31.9%29.2% of our pretax income, compared to approximately $243,000$983,000 in 2015the year ended December 31, 2016, or 34.5%31.9% of our pretax income. Our lowerThe increase in our provision for income taxes, which principally was due to the increase in our operating income, was offset in part by the benefit reflecting the reduction of our U.S. corporate income tax rate from 34% to 21% under the Tax Cuts and Jobs Act. We revalued our net deferred tax liabilities to give effect to the reduction in 2016 is attributable primarily tothe corporate income tax rate, which resulted in an increased benefit with respect to a domestic production activities deduction.approximately $91,000 tax benefit. For additional information, see Note 8 to the consolidated financial statements included in this report.

 

Liquidity and Capital Resources:

 

Our cash balance was approximately $2,418,000 at December 31, 2017 compared to approximately $4,070,000 at December 31, 2016 compared to approximately $2,468,000 at December 31, 2015.2016.  

 

The following table summarizes our cash flows for the years ended December 31, 20162017 and 2015:2016:

  

Years Ended

December 31,

 
  2017  2016 
Net cash provided by operating activities $2,928,277  $3,025,585 
Net cash used in investing activities  (8,023,092)  (443,892)
Net cash provided by (used in) financing activities  3,442,826   (978,503)
Effect of exchange rate fluctuations on cash  28   (1,160)
Net (decrease) increase in cash $(1,651,961) $1,602,030 

  

  

Years Ended

December 31,

 
  2016  2015 
Net cash provided by operating activities $3,025,585  $812,463 
Net cash used in investing activities  (443,892)  (954,663)
Net cash used in financing activities  (978,503)  (450,598)
Effect of exchange rate fluctuations on cash  (1,160)  (1,516)
Net increase (decrease) in cash $1,602,030  $(594,314)

9

 

Net cash provided by operating activities for the year ended December 31, 2016 increased2017 decreased by approximately $2,213,000$97,000 or 272.4%3.2%, as compared to the year ended December 31, 2015.2016. The comparative increasedecrease is attributable to changes in cash provided by operating activitiesworking capital (excluding cash) of approximately $1,099,000 for the year ended December 31, 2017 as compared to changes of approximately $344,000 during the year ended December 31, 2016 is attributable to2016. These changes were mostly offset by an increase in net income of approximately $1,634,000 increased$508,000 combined with an increase of noncash expenses of approximately $61,000, and net favorable changes in working capital (excluding cash) of $517,000$158,000 during the year ended December 31, 2017 as compared to the same period in 2015.year ended December 31, 2016.

 

Inventories, net were approximately $8,601,000$9,074,000 and $7,915,000$8,601,000 at December 31, 20162017 and 2015,2016, respectively, representing an increase of approximately $686,000$473,000 or 8.7%5.5% in 2016.2017. The 20162017 increase in inventories reflects anticipated demand in the first quarter of 2017. Moreover, inventory levels at December 31, 2015 reflect the shipment of a large order a major customer in late December 2016.2018.

 

Net trade accounts receivable at December 31, 20162017 aggregated approximately $4,932,000, a decrease$4,964,000, an increase of approximately $160,000$32,000 or 3.1%0.7% compared to approximately $5,092,000$4,932,000 in net trade accounts receivable outstanding at December 31, 2015.2016.  Receivables due from affiliated companies aggregated approximately $1,190,000$1,584,000 at December 31, 2016,2017, an increase of approximately $139,000,$394,000, or 13.2%33.1% over receivables due from affiliated companies of approximately $1,051,000$1,190,000 at December 31, 2015.2016.

 

9

Net cash used in investing activities for the year ended December 31, 2016 decreased2017 increased by approximately $511,000 or 53.5%,$7,579,000, as compared to the year ended December 31, 2015. Our purchases2016. The increase is primarily attributable to expenditures related to the Expansion Project and the classification of property, plant and equipment during 2016, principally consisting of manufacturing equipment, was considerably below the level of such purchases in 2015. Net cash used in investing activities during the year ended December 31, 2015 was offset in small part byunused cash proceeds of $55,000an industrial development bond financing with respect to the Expansion Project as restricted cash. The classification results from a lease agreement that places limitations on our use of cash we received from the sale of a recreational vehicle we usedindustrial development bond financing. See “Overview” above and Note 6 to the consolidated financial statements included in this report for advertising and exhibiting our products at trade shows and other events.additional information.

 

Net cash used inprovided by financing activities for the year ended December 31, 2016 increased by2017 was approximately $528,000, or 117.2%, as$3,400,000 compared to net cash used of approximately $979,000 for the year ended December 31, 2015. The increase in2016. During the 2016 period is principally dueyear ended December 31, 2017, we received proceeds of $4,500,000 from the industrial development bond financing relating to our payment ofthe Expansion Project and had lower payments on long term debt because a specialterm loan that had been outstanding since 2011 matured on July 6, 2017, at which date we repaid all outstanding principal and interest. These increases to cash dividend aggregating approximately $541,000,were partially offset by approximately $22,000 we received as a result of the exercise of stock options.payments for debt issuance costs.

 

See Notes 4 and 6 to the consolidated financial statements included in this report for information concerning our principal credit facilities, consisting of Kinpak’s obligations relating to an industrial development bond financing, the payment of which we have guaranteed and a revolving line of credit and a term loan.credit. At December 31, 20162017 and 2015,2016, we had outstanding balances of approximately $4,463,000 and $260,000, under Kinpak’s obligations relating to the industrial development bond financing and a previously outstanding term loan respectively, and no borrowings under our current and previous revolving credit facilities. The loan agreement pertaining to our revolving line of credit, and outstanding balances of approximately $260,000 and $692,000, respectively, under our term loan. The loan agreement related to our revolving line of creditas amended, contains various covenants, including financial covenants requiring a minimum debtfixed charge coverage ratio (generally, EBITDAR (net operating profit plus depreciation, amortizationthe ratio of (A) EBITDA for the four most recently completed fiscal quarters minus the sum of Company’s distributions to its shareholders, taxes paid and lease/rent expense) divided byunfunded capital expenditures during such period to (B) current maturities of Company long-term debt (as defined) as of the end of the most recent fiscal quarter plus scheduled interest and lease/rent expense)expense incurred over the most recently completed four fiscal quarters) of 1.751.20 to 1.00, calculated on a trailing twelve month basis,1, tested quarterly and a maximum debt“debt to capitalizationcap” ratio (generally, funded debt divided by the sum of total net worth and funded debt) of 0.75 to 1 calculated quarterly. Atas of the end of each fiscal quarter. The agreement relating to the revolving line of credit generally defines “long term debt”  as  “debt instruments with a maturity principal due date of one year or more in length,” including, among other listed contractual debt instruments, “revolving lines of credit” and “capital leases obligations.”Our guarantee of Kinpak’s obligations related to the industrial development bond financing effectively is subject to substantially the same financial covenants. For the year ended December 31, 2016, our debt2017, the Company’s fixed charge coverage ratio was approximately 10.607.30 to 1.00, and ourat December 31, 2017, the Company’s debt to capitalization ratio was approximately 0.020.15 to 1.00.

 

In addition to our term loan,the industrial revenue bond financing and the revolving line of credit, we have obtained financing through capital leases for office equipment, totaling approximately $69,000$50,000 and $88,000$69,000 at December 30,31, 2017 and 2016, and December 31, 2015, respectively.

 

Some of our assets and liabilities are denominated in Canadian dollars and are subject to currency exchange rate fluctuations. We do not engage in currency hedging and address currency risk as a pricing issue. InFor the year ended December 31, 2016,2017, we recorded $2,113$1,496 in foreign currency translation adjustments (decreasing shareholders’ equity by $2,113)$1,496).

 

During the past few years, we have introduced a number of new products.  At times, new product introductions have required us to increase our overall inventory and have resulted in lower inventory turnover rates.  The effects of reduced inventory turnover have not been material to our overall operations.  We believe that all capital required to fund any inventory increases will continue to be provided by operations and, if necessary, our current revolving line of credit or a renewal or replacement of the facility.  However, we cannot assure that we will be able to secure such a renewal or replacement of our revolving line of credit.

 

Many of the raw materials that we use in the manufacturing process are petroleum or chemical based and commodity chemicals that are subject to fluctuating prices. The nature of our business does not enable us to pass through the price increases to our national retailer customers and to our distributors as promptly as we experience increases in raw material costs. This may, at times, adversely affect our margins.

 

As noted above, we are in the Company is proceeding with a project to expand Kinpak’s manufacturing, warehouse and distribution facilities in Montgomery, Alabama. As currently contemplated,final stages of the project will entailExpansion Project, which entails an approximately 85,000 square feet addition to theKinpak’s manufacturing facilities and an expansion of Kinpak’s outdoor blended tank farm to accommodate an additional 500,000 gallons in tank capacity, thereby doubling the tank farm’s current capacity. The first phase ofaddition to the project, involvingfacilities and expansion of the tank farm was initiated earlier in 2017. We are using internal funds for this phase, although we currently are in negotiations to finance the costscompleted. The remaining parts of the entire project. Nevertheless,Expansion Project involve additional upgrades to the warehouse facilities and the installation of new manufacturing equipment. At December 31, 2017, expenditures in connection with the Expansion Project aggregated approximately $5.1 million, and we cannot assure that such financing will be obtained. We currently estimate that the projecttotal cost of the Expansion Project will be approximately $4.7$6.0 million. The Expansion Project is expected to be completed and placed into service during 2018. The Expansion Project is being financed primarily with the proceeds of the industrial development bond financing, which is described in Note 6 to the consolidated financial statements included in this report. The Expansion Project also is being funded with cash from operations.

10

 

We believe that funds provided through operations and other sources of financing will be sufficient to satisfy our cash requirements over at least the next twelve months. However, in the event that we are not able to obtain additional financing for our expansion project, completion of the project may be delayed.

 

Item 7A. Quantitative and Qualitative Disclosure about Market Risk

 

Not applicable.

 

Item 8.    Financial Statements and Supplementary Data

 

The audited financial statements of the Company required pursuant to this Item 8 are included in a separate section commencing on page F-1 and are incorporated herein by reference.

 

Item 9.    Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

 

Not applicable.

 

10

Item 9A.  Controls and Procedures:

 

Evaluation of Disclosure Controls and Procedures.  The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"“Exchange Act”)) at the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that as of the end of the period covered by this report, the Company’s disclosure controls and procedures are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act are (i) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and (ii) accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

 

Change in Internal Controls over Financial Reporting.  No change in internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) occurred during the Company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

Management’s Annual Report on Internal Control over Financial Reporting

 

Management of Ocean Bio-Chem, Inc. is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Management evaluated the Company’s internal control over financial reporting as of December 31, 2016.2017. In making this assessment, management used the framework established inInternal Control-Integrated Framework(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). As a result of this assessment and based on the criteria in the COSO framework, management has concluded that, as of December 31, 2016,2017, the Company’s internal control over financial reporting was effective.

 

Item 9B.  Other Information

 

Not applicable.

 

11

PART III

 

Item 10.  Directors, Executive Officers and Corporate Governance

 

Information required by this item is incorporated by reference to the Company'sCompany’s definitive proxy statement, which will be filed with the Commission no later than 120 days after the close of the fiscal year covered by this report.

 

Item 11.  Executive Compensation

 

Information required by this item is incorporated by reference to the Company'sCompany’s definitive proxy statement, which will be filed with the Commission no later than 120 days after the close of the fiscal year covered by this report.

 

Item 12.  Security Ownership of Certain Beneficial Owners and Management and Related ShareholderStockholder Matters

 

Information required by this item is incorporated by reference to the Company'sCompany’s definitive proxy statement, which will be filed with the Commission no later than 120 days after the close of the fiscal year covered by this report.

 

Item 13.  Certain Relationships and Related Transactions, and Director Independence

 

Information required by this item is incorporated by reference to the Company'sCompany’s definitive proxy statement, which will be filed with the Commission no later than 120 days after the close of the fiscal year covered by this report.

 

Item 14.  Principal Accounting Fees and Services

 

Information required by this item is incorporated by reference to the Company'sCompany’s definitive proxy statement, which will be filed with the Commission no later than 120 days after the close of the fiscal year covered by this report.

 

 1112 

 

PART IV

Item 15.  Exhibits, Financial Statements,Statement Schedules and Reports Filed on Form 8K

 

(a)Financial Statements – See the Index to Consolidated Financial Statements on page F-1.

(b)

(b)

Exhibits:

  
 

Unless otherwise noted, the file number of each referenced filing is 0-11102.

 

Exhibit No. 
3.1.1Articles of Incorporation and amendments through May 20, 1994 (incorporated by reference to Exhibit 3.1 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2010).
3.1.2Articles of Amendment to the Articles of Incorporation, as filed on June 13, 2012 (incorporated by reference to Exhibit 3.1.2 to the Company's Annual Report on Form 10-K for the year ended December 31, 2012).
3.2   Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on December 5, 2011).
*10.110.1.1Business Loan Agreement, dated November 17, 2016,August 31, 2017, between the Company and Regions Bank (the “Business Loan Agreement”) (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017).
*10.210.1.2Promissory Note, dated November 17, 2016,August 31, 2017, issued by the Company to Regions Bank in connection with the revolving line of credit under the Business Loan Agreement (the “Promissory Note”) (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017).
*10.310.1.3Letter, dated November 17, 2016,August 31, 2017, from Regions Bank to the Company, regarding certain terms under the Business Loan Agreement and the Promissory Note.Note (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017).
†10.4*10.1.4Letter, dated December 20, 2017, from Regions Bank to the Company, regarding certain terms of the Business Loan Agreement.
10.2Ocean Bio-Chem, Inc. 2015 Equity Compensation Plan, as amended (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 12, 2016).
10.5Credit Agreement, dated July 6, 2011, among the Company, Kinpak,10.3.1Form of Industrial Development Revenue Bond (Kinpak Inc. and Regions Bank (the “Credit Agreement”)Project) Series 2017 (incorporated by reference to Exhibit 10.299.1 to the Company’s QuarterlyCurrent Report on Form 10-Q for8-K, filed with the quarter ended September 30, 2011)Securities and Exchange Commission on October 2, 2017).
10.6Equipment Finance Addendum,10.3.2Second Restated Lease Agreement, dated July 6, 2011, amongas of September 1, 2017, between The Industrial Development Board of the Company, Kinpak,City of Montgomery and KINPAK, Inc. and Regions Equipment Finance Corporation (incorporated by reference to Exhibit 10.199.2 to the Company’s QuarterlyCurrent Report on Form 10-Q for8-K, filed with the quarter ended September 30, 2011)Securities and Exchange Commission on October 2, 2017).
10.7Promissory Note,10.3.3

Mortgage, Security Agreement and Assignment of Rents and Leases, dated July 6, 2011, issuedas of September 1, 2017, provided by The Industrial Development Board of the CompanyCity of Montgomery and Kinpak,KINPAK, Inc. (incorporated by reference to Regions Equipment Finance Corporation in connectionExhibit 99.3 to the Company’s Current Report on Form 8-K, filed with the term loan under the CreditSecurities and Exchange Commission on October 2, 2017).

10.3.4Guaranty Agreement, dated as of September 1, 2017, provided by Ocean Bio-Chem, Inc. and its consolidated subsidiaries party thereto  (incorporated by reference to Exhibit 99.4 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 12, 2011)October 2, 2017).
 †10.8†10.4Ocean Bio-Chem, Inc. 2002 Non-Qualified Stock Option Plan, as amended (incorporated by reference to Exhibit 99.2 to the Company’s Registration Statement on Form S-8 (File No. 333-176268), filed with the Securities and Exchange Commission on August 12, 2011).
 †10.9†10.5Ocean Bio-Chem, Inc. 2008 Non-Qualified Stock Option Plan, as amended (incorporated by reference to Exhibit 99.5 to the Company’s Registration Statement on Form S-8 (File No. 333-176268), filed with the Securities and Exchange Commission on August 12, 2011).
10.1010.6.1Net Lease, dated May 1, 1998, between Star Brite Distributing, Inc. and PEJE, IncInc. (incorporated by reference to Exhibit 10.14 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2004).
10.1110.6.2Renewal of Lease, dated May 1, 2008, between Star Brite Distributing, Inc. and PEJE, Inc. (incorporated by reference to Exhibit 10.24 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2008).
10.1210.6.3Amendment Number Two to Net Lease, dated May 16, 2013, between Star Brite Distributing, Inc. and PEJE, Inc. (incorporated by reference to Exhibit 10.13 to the Company's Annual Report on Form 10-K for the year ended December 31, 2013).
*21   List of Subsidiaries
*23.1*23Consent of Goldstein Schechter Koch, P.A. Independent Registered Public Accounting Firm.EisnerAmper LLP
*31.2*31.1Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act.
*31.2Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act.
*32.1Certification of Chief Executive Officer pursuant to Rule 13a-14(b) under the Securities Exchange Act and 18 U.S.C. Section 1350.
*32.2Certification of Chief Financial Officer pursuant to Rule 13a-14(b) under the Securities Exchange Act and 18 U.S.C. Section 1350.
101

The following materials from Ocean Bio-Chem Inc.’s Annual Report on Form 10-K for the year ended December 31, 2016,2017, formatted in XBLR (eXtensible Business Reporting Language):  (i) Consolidated Balance Sheets at December 31, 20162017 and December 31, 2015;2016; (ii) Consolidated Statements of Operations for the years ended December 31, 201631, 2017 and 2015;2016; (iii) Consolidated Statements of Comprehensive Income for the years ended December 31, 20162017 and 2015;2016; (iv) Consolidated Statements of Changes in Shareholders Equity for the years ended December 31, 20162017 and 2015,2016, (v) Consolidated Statements of Cash Flows for the years ended December 31, 20162017 and 20152016 and (vi) Notes to Consolidated Financial Statements.

*     Filed herewith.

†     Constitutes management contract or compensatory plan or arrangement required to be filed as in exhibit to this report. 

*Filed herewith.
Constitutes management contract or compensatory plan or arrangement required to be filed as in exhibit to this report.  

  

Item 16.  Form 10-K Summary

Registrants may voluntarily include a summary of information required by Form 10-K under this Item 16. The Company has elected not to include a summary

 1213 

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 OCEAN BIO-CHEM, INC.
   
Date: March 31, 201730, 2018By:/s/ Peter G. Dornau     
  PETER G. DORNAU
  Chairman of the Board, President and
  

Chief Executive Officer

(Principal Executive Officer)

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

 

Signature Capacity Date
     
/s/ Peter G. Dornau Chairman of the Board, President and March 31, 201730, 2018
Peter G. Dornau Chief Executive Officer  
  (Principal Executive Officer)  
     
/s/Jeffrey S. Barocas Vice President, Chief Financial Officer March 31, 201730, 2018
Jeffrey S. Barocas (Principal Financial and Accounting Officer)  
     
/s/ Diana Mazuelos Conard Director March 31, 201730, 2018
Diana Mazuelos Conard    
     
/s/ Gregor M. Dornau Director March 31, 201730, 2018
Gregor M. Dornau    
     
/s/ William W. Dudman Director March 31, 201730, 2018
William W. Dudman    
     
/s/ James M. Kolisch Director March 31, 201730, 2018
James M. Kolisch    
     
/s/ Kimberly A. Krause Director March 31, 201730, 2018
Kimberly A. Krause    
     
/s/ John B. Turner Director March 31, 201730, 2018
John B. Turner    

 

 1314 

 

 

OCEAN BIO-CHEM, INC. AND SUBSIDIARIES

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

 Page
ReportsReport of independent registered public accounting firmsfirmF-2 -
Consolidated balance sheetsF-3
  
Consolidated balance sheetsstatements of operationsF-4
  
Consolidated statements of operationscomprehensive incomeF-5
  
Consolidated statements of comprehensive incomeshareholders’ equityF-6
  
Consolidated statements of changes in shareholders’ equitycash flowsF-7
  
Consolidated statements of cash flowsF-8
Notes to consolidated financial statementsF-9F-8 - F-18F-17

F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and Shareholders of

Ocean Bio-Chem,Bio Chem, Inc. and Subsidiaries

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheetsheets of Ocean Bio-Chem, Inc. and Subsidiaries (the “Company") as of December 31, 2017 and 2016 and the related consolidated statements of operations, comprehensive income, changes in shareholders’ equity, and cash flows for each of the yearyears then ended. Ocean Bio-Chem, Inc.'s management is responsible for theseended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the consolidated financial statements.position of the Company as of December 31, 2017 and 2016 and the consolidated results of their operations and their cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidatedthe Company’s financial statements based on our audit.audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our auditaudits in accordance with the standards of the Public Company Accounting Oversight Board (United States).PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included considerationAs part of our audits we are required to obtain an understanding of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’sCompany's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence supportingregarding the amounts and disclosures in the consolidated financial statements, assessingstatements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statement presentation.statements. We believe that our audit providesaudits provide a reasonable basis for our opinion.

  

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Ocean Bio-Chem, Inc. and Subsidiaries as of December 31, 2016, and the results of their operations and their cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.

/s/ EisnerAmper LLP

 

Fort Lauderdale, FloridaWe have served as the Company’s auditor since 2017.

 

March 31, 2017

F-2 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Shareholders of

Ocean Bio-Chem, Inc. and Subsidiaries

We have audited the accompanying consolidated balance sheet of Ocean Bio-Chem, Inc. and Subsidiaries as of December 31, 2015 and the related consolidated statements of operations, comprehensive income, changes in shareholders’ equity, and cash flows for the year then ended. Ocean Bio-Chem, Inc.'s management is responsible for these consolidated financial statements. Our responsibility is to express an opinion on these consolidated financial statements based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Ocean Bio-Chem, Inc. and Subsidiaries as of December 31, 2015 and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.

/s/ Goldstein Schechter Koch P.A.

Certified Public Accountants

EISNERAMPER LLP

Fort Lauderdale, Florida

March 30, 20162018

 

F-2

 

OCEAN BIO-CHEM, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

DECEMBER 31, 20162017 AND 20152016

 

  2016  2015 
       
ASSETS        
Current Assets:        
Cash $4,070,445  $2,468,415 
Trade accounts receivable less allowances of approximately $75,000 and $78,000, respectively  4,931,792   5,092,040 
Receivables due from affiliated companies  1,190,103   1,051,091 
Inventories, net  8,600,689   7,914,950 
Prepaid expenses and other current assets  1,013,952   942,820 
Total Current Assets  19,806,981   17,469,316 
         
Property, plant and equipment, net  4,895,973   5,356,388 
Intangible assets, net  967,688   1,037,968 
Total Assets $25,670,642  $23,863,672 
         
LIABILITIES AND SHAREHOLDERS' EQUITY        
Current Liabilities:        
Current portion of long-term debt $278,392  $451,148 
Accounts payable - trade  1,512,020   1,101,720 
Income taxes payable  1,447   - 
Accrued expenses payable  1,099,919   1,098,721 
Total Current Liabilities  2,891,778   2,651,589 
         
Deferred tax liability  213,367   239,677 
Long-term debt, less current portion  50,426   328,818 
Total Liabilities  3,155,571   3,220,084 
         
Commitments and contingencies        
Shareholders' Equity:        
Common stock - $.01 par value, 12,000,000 shares authorized; 9,146,937 shares and 8,983,374 shares issued, respectively  91,469   89,834 
Additional paid in capital  9,604,634   9,287,313 
Accumulated other comprehensive loss  (286,555)  (284,442)
Retained earnings  13,105,523   11,550,883 
Total Shareholders' Equity  22,515,071   20,643,588 
         
Total Liabilities and Shareholders' Equity $25,670,642  $23,863,672 
         

  2017  2016 
       
ASSETS      
Current Assets:      
Cash $2,418,484  $4,070,445 
Trade accounts receivable less allowances of approximately $79,000 and $75,000, respectively  4,963,895   4,931,792 
Receivables due from affiliated companies  1,584,365   1,190,103 
Restricted cash  2,747,360   --- 
Inventories, net  9,074,426   8,600,689 
Prepaid expenses and other current assets  1,013,213   1,013,952 
Total Current Assets  21,801,743   19,806,981 
         
Property, plant and equipment, net  9,291,667   4,895,973 
Intangible assets, net  897,408   967,688 
Total Assets $31,990,818  $25,670,642 
         
LIABILITIES AND SHAREHOLDERS’ EQUITY        
Current Liabilities:        
Current portion of long-term debt, net $240,017  $278,392 
Accounts payable - trade  1,807,120   1,512,020 
Income taxes payable  ---   1,447 
Accrued expenses payable  812,062   1,099,919 
Total Current Liabilities  2,859,199   2,891,778 
         
Deferred tax liability  153,895   213,367 
Long-term debt, less current portion and debt issuance costs  4,081,793   50,426 
Total Liabilities  7,094,887   3,155,571 
         
Commitments and contingencies        
Shareholders’ Equity:        
Common stock - $.01 par value, 12,000,000 shares authorized; 9,254,580 shares and 9,146,937 shares issued, respectively  92,546   91,469 
Additional paid in capital  9,931,634   9,604,634 
Accumulated other comprehensive loss  (288,051)  (286,555)
Retained earnings  15,159,802   13,105,523 
Total Shareholders’ Equity  24,895,931   22,515,071 
         
Total Liabilities and Shareholders’ Equity $31,990,818  $25,670,642 

 

The accompanying notes are an integral part of these consolidated financial statements.                

 

F-3

OCEAN BIO-CHEM, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

YEARS ENDED DECEMBER 31, 20162017 AND 20152016

 

 2016  2015  2017  2016 
          

Net sales

 $36,205,444  $33,987,487  $38,933,458  $36,205,444 
                
Cost of goods sold  22,331,761   22,647,516   24,436,780   22,331,761 
                
Gross profit  13,873,683   11,339,971   14,496,678   13,873,683 
                
Operating Expenses:                
Advertising and promotion  3,117,164   3,010,758   3,523,710   3,117,164 
Selling and administrative  7,660,377   7,579,682   7,297,538   7,660,377 
Total operating expenses  10,777,541   10,590,440   10,821,248   10,777,541 
                
Operating income  3,096,142   749,531   3,675,430   3,096,142 
                
Other expense        
Interest net, (expense)  (17,820)  (33,639)
Other (expense)  ---   (12,522)
Other income (expense)        
Interest net, income (expense)  2,065   (17,820)
                
Income before income taxes  3,078,322   703,370   3,677,495   3,078,322 
                
Provision for income taxes  (983,151)  (242,676)  (1,073,961)  (983,151)
                
Net income $2,095,171  $460,694  $2,603,534  $2,095,171 
                
Earnings per common share – basic and diluted $0.23  $0.05  $0.28  $0.23 
                
Dividends declared per common share $0.06  $----  $0.06  $0.06 

The accompanying notes are an integral part of these consolidated financial statements.                

F-4

OCEAN BIO-CHEM, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

YEARS ENDED DECEMBER 31, 2017 AND 2016

  2017  2016 
       
Net income $2,603,534  $2,095,171 
         
Foreign currency translation adjustment  (1,496)  (2,113)
         
Comprehensive income $2,602,038  $2,093,058 

The accompanying notes are an integral part of these consolidated financial statements.  

F-5

OCEAN BIO-CHEM, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

YEARS ENDED DECEMBER 31, 2017 AND 2016

     Additional  Accumulated Other       
  Common Stock  Paid In  Comprehensive  Retained    
  Shares  Amount  Capital  loss  Earnings  Total 
                   
January 1, 2016  8,983,374  $89,834  $9,287,313  $(284,442) $11,550,883  $20,643,588 
                         
Net income                  2,095,171   2,095,171 
                         
Dividends declared and paid                  (540,531)  (540,531)
                         
Options exercised  25,481   255   21,345           21,600 
                         
Common stock issued, net of shares withheld for employee taxes  138,082   1,380   295,976           297,356 
                         
Foreign currency
translation adjustment
              (2,113)      (2,113)
                         
December 31, 2016  9,146,937  $91,469  $9,604,634  $(286,555) $13,105,523  $22,515,071 
                         
Net income                  2,603,534   2,603,534 
                         
Dividends declared and paid                  (549,255)  (549,255)
                         
Options exercised  34,043   341   26,059           26,400 
                         
Common stock issued, net of shares withheld for employee taxes  73,600   736   300,941           301,677 
                         
Foreign currency translation adjustment              (1,496)      (1,496)
                         
December 31, 2017  9,254,580  $92,546  $9,931,634  $(288,051) $15,159,802  $24,895,931 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-5F-6 

 

OCEAN BIO-CHEM, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOMECASH FLOWS

YEARS ENDED DECEMBER 31, 20162017 AND 20152016

 

  2016  2015 
       
Net income $2,095,171  $460,694 
         
Foreign currency translation adjustment  (2,113)  (5,279)
         
Comprehensive income $2,093,058  $455,415 
  2017  2016 
Cash flows from operating activities:      
       
Net income $2,603,534  $2,095,171 
Adjustment to reconcile net income to net cash provided by operations:        
Depreciation and amortization  955,161   974,587 
Deferred income taxes  (59,472)  (26,310)
Stock based compensation  324,145   305,780 
Provision for bad debts  198,839   (3,272)
Other operating noncash items  4,612   14,044 
         
Changes in assets and liabilities:        
Trade accounts receivable  (230,942)  163,520 
Receivables due from affiliated companies  (394,262)  (139,012)
Inventories  (479,873)  (700,736)
Prepaid expenses and other current assets  739   (71,132)
Accounts payable  295,100   410,300 
Income taxes payable  (1,447)  1,447 
Accrued expenses payable  (287,857)  1,198 
Net cash provided by operating activities  2,928,277   3,025,585 
         
Cash flows from investing activities:        
Purchases of property, plant and equipment  (5,275,732)  (443,892)
Increase in cash restricted for plant expansion  (2,747,360)  --- 
Net cash used in investing activities  (8,023,092)  (443,892)
         

Cash flows from financing activities:

        
Proceeds from long term debt  4,500,000   --- 
Payments on long-term debt  (315,756)  (451,148)
Borrowings on revolving line of credit  1,000,000   --- 
Repayments on revolving line of credit  (1,000,000)  --- 
Payments for taxes related to net share settlements of stock awards  (22,468)  (8,424)
Dividends paid to common shareholders  (549,255)  (540,531)
Payments for debt issuance costs  (196,095)  --- 
Proceeds from exercise of stock options  26,400   21,600 
Net cash provided by (used in) financing activities  3,442,826   (978,503)
Effect of exchange rate on cash  28   (1,160)
Net (decrease) increase in cash  (1,651,961)  1,602,030 
Cash at beginning of the year  4,070,445   2,468,415 
Cash at end of the year $2,418,484  $4,070,445 
Supplemental disclosure of cash transactions:        
Cash paid for interest during the year $29,496  $19,096 
Cash paid for income taxes during the year $1,282,400  $993,600 

 

The accompanying notes are an integral part of these consolidated financial statements.                

 

F-7

OCEAN BIO-CHEM, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

YEARS ENDED DECEMBER 31, 2016 AND 2015

  Common Stock   Additional Paid In  Accumulated Other Comprehensive   Retained    
   Shares   Amount  Capital  loss   Earnings  Total 
                   
January 1, 2015  8,914,274  $89,142  $9,131,952  $(279,163) $11,090,189  $20,032,120 
                         
Net income
                 460,694   460,694 
                         
Options exercised  7,844   79   (79)          --- 
                         
Common stock issued, net of shares withheld for employee taxes  61,256   613   155,440           156,053 
                         
Foreign currency
translation adjustment
              (5,279)      (5,279)
                         
December 31, 2015  8,983,374  $89,834  $9,287,313  $(284,442) $11,550,883  $20,643,588 
                         

Net income

                  2,095,171   2,095,171 
                         
Dividends declared                  (540,531)  (540,531)
                         
Options exercised  25,481   255   21,345           21,600 
                         
Common stock issued, net of shares withheld for employee taxes  138,082   1,380   295,976           297,356 
                        
Foreign currency translation adjustment              (2,113)      (2,113)
                         
December 31, 2016  9,146,937  $91,469  $9,604,634  $(286,555) $13,105,523  $22,515,071 

The accompanying notes are an integral part of these consolidated financial statements.

F-7 

OCEAN BIO-CHEM, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

YEARS ENDED DECEMBER 31, 2016 AND 2015

  2016  2015 
Cash flows from operating activities:        
         
Net income $2,095,171  $460,694 
Adjustment to reconcile net income to net cash provided by operations:        
Depreciation and amortization  974,587   916,317 
Deferred income taxes  (26,310)  104,355 
Loss on sale of property, plant and equipment  -   12,522 
Stock based compensation  305,780   168,663 
Other operating noncash items  10,772   1,578 
         
Changes in assets and liabilities:        
Trade accounts receivable  163,520   (244,513)
Inventories  (700,736)  191,797 
Prepaid expenses and other current assets  (71,132)  (91,487)
Receivables due from affiliated companies  (139,012)  (336,057)
Accounts payable  410,300   (338,148)
Accrued expenses payable  2,645   (33,258)
Net cash provided by operating activities  3,025,585   812,463 
         
Cash flows from investing activities:        
Purchases of property, plant and equipment  (443,892)  (997,761)
Cash paid for patent and trademark registration  -   (11,902)
Sale of property, plant and equipment  -   55,000 
Net cash used in investing activities  (443,892)  (954,663)
Cash flows from financing activities:        
Payments on long-term debt  (451,148)  (437,988)
Payments for taxes related to net share settlements of stock awards  (8,424)  (12,610)
Dividends paid to common shareholders  (540,531)  - 
Proceeds from exercise of stock options  21,600   - 
Net cash used in financing activities  (978,503)  (450,598)
Effect of exchange rate on cash  (1,160)  (1,516)
Net increase (decrease) increase in cash  1,602,030   (594,314)
Cash at beginning of the year  2,468,415   3,062,729 
Cash at end of the year $4,070,445  $2,468,415 
Supplemental disclosure of cash transactions:        
Cash paid for interest during the year $19,096  $34,871 
Cash paid for income taxes during the year $993,600  $169,200 

The accompanying notes are an integral part of these consolidated financial statements.                

OCEAN BIO-CHEM, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED DECEMBER 31, 20162017 AND 20152016

 

Note 1 – Organization and summary of significant accounting policies:

 

Organization – The Company was incorporated in November 1973 under the laws of the state of Florida and manufacturers, markets and distributes products, principally under the Star brite® and Star Tron® brands,brand names, for the marine, automotive, power sports, recreational vehicle and outdoor power equipment markets.markets in the United States and Canada. In addition, the Company produces private label formulations of many of its products for various customers and provides custom blending and packaging services for these and other products. The Company also manufactures disinfectants, sanitizers and deodorizers under the Performacide® and Star brite® brand names.

 

Basis of presentation – The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation. Certain prior-period data have been reclassified to conform to the current period presentation.

 

Revenue recognition – Revenue from product sales is recognized when persuasive evidence of a contract exists, the sales price is fixed and determinable, the title of goods passes to the customer, and collectability of the related receivable is probable. Reported net sales are net of customer prompt pay discounts, contractual allowances, authorized customer returns, consumer rebates and other sales incentives.

 

Collectability of accounts receivable – Trade accounts receivable at December 31, 20162017 and 20152016 are net of allowances for doubtful accounts aggregating approximately $75,000$79,000 and $78,000,$75,000, respectively. Such amounts are based on management's estimatesexpected collectability of the creditworthinesstrade accounts receivable, after considering the Company’s historical collection experience, the length of its customers, current economic conditionstime an account is outstanding, the financial position of the customer if known and historical information.information provided by credit rating services. During the year ended December 31, 2015,2017, the Company recorded bad debt expense of approximately $3,000.$199,000. During the year ended December 31, 2016, the Company reduced its bad debt reserve by approximately $3,000, resulting in an increase to net income.

 

Inventories– Inventories are primarily composed of raw materials and finished goods and are stated at the lower of cost, using the first-in, first-out method, or market.

 

Shipping and handling costs – All shipping and handling costs incurred by the Company are included in cost of goods sold in the consolidated statements of operations. Shipping and handling costs totaled approximately $1,120,000$1,226,000 and $1,367,000$1,120,000 for the years ended December 31, 20162017 and 2015,2016, respectively.

 

Advertising and promotion expense – Advertising and promotion expense consists of advertising costs and marketing expenses, including catalog costs and expenses relating to participation at trade shows. Advertising costs are expensed in the period in which the advertising occurs and totaled approximately $3,524,000 and $3,117,000 in 2017 and $3,011,000 in 2016, and 2015, respectively.

 

Property, plant and equipment – Property, plant and equipment is stated at cost, net of depreciation. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method. Depreciation expense totaled $904,307$884,881 and $846,925$904,307 for the years ended December 31, 2017 and 2016, and 2015, respectively.

 

Research and development costs – Research and development costs are expensed as incurred and recorded in selling and administrative expenses in the consolidated statements of operations. The Company incurred approximately $46,000$42,000 and $78,000$46,000 of research and development costs for the years ended December 31, 2017 and 2016, and 2015, respectively.

 

Stock based compensation – The Company records stock-based compensation in accordance with the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC") Topic 718, "Accounting for Stock Compensation," which establishes accounting standards for transactions in which an entity exchanges its equity instruments for goods or services. In accordance with guidance provided under ASC Topic 718, we recognize an expense for the fair value of our stock awards at the time of grant and the fair value of our outstanding stock options as they vest, whether held by employees or others. As of December 31, 2016,2017, all outstanding stock options were vested.

 

Use of estimates – The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

F-8

Concentration of cash– At various times during the yearyears ended and at December 31, 20162017 and 2015,2016, the Company had a concentration of cash in one bank in excess of prevailing insurance offered through the Federal Deposit Insurance Corporation at such institution.  Management does not consider the excess deposits to be a significant risk.

 

Fair value of financial instruments – ASC Topic 820, “Fair Value Measurements and Disclosures” defines “fair value” as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

 

ASC Topic 820 also sets forth a valuation hierarchy of the inputs (assumptions that market participants would use in pricing an asset or liability) used to measure fair value. The hierarchy prioritizes the three levels of inputs into the following three levels:as follows:

 

 Level 1: Observable inputs that reflect unadjusted quoted prices for identical assets or liabilities traded in active markets.
  
 Level 2: Inputs that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data through correlation or other means.
  
 Level 3: Inputs that are generally unobservable. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value.

 

The carrying amounts of the Company’s short-term financial instruments, including cash, accounts receivable, accounts payable, certain accrued expenses and revolving  line of credit,  approximate their fair value due to the relatively short period to maturity for these instruments.  The fair value of long-term debt is based on current rates at which the Company could borrow funds with similar remaining maturities; the carrying amount of the long-term debt approximates fair value.

 

Impairment of long-lived assets – Potential impairments of long-lived assets are reviewed when events or changes in circumstances indicate a potential impairment may exist.  In accordance with ASC Subtopic 360-10, "Property,“Property, Plant and Equipment – Overall," impairment is determined when estimated future undiscounted cash flows associated with an asset are less than the asset’s carrying value.

 

Income taxes – The Company records income taxes under the asset and liability method. TheUnder this method, the Company recognizes deferred income tax assets and liabilities for the expected future consequences ofattributable to temporary differences between the financial reporting and tax bases of assets and liabilities. These differences are measured using tax rates that are expected to apply to taxable income in the years in which those temporary differences are recovered or settled. We recognize in the statement of operations the effect on deferred income taxes of a change in tax rates in the period in which the change is enacted.

 

We record a valuation allowance when necessary to reduce our deferred tax assets to the net amount that we believe is more likely than not to be realized. We consider all available evidence, both positive and negative, and use judgments regarding past and future events, including historical levels of income, expectationsoperating results and risks associated with estimates of future taxable income and ongoingavailable tax planning strategies, in assessing the need for a valuation allowance.

 

We recognize tax benefits from uncertain tax positions only if we believe that it is more likely than not that the tax positions will be sustained on examination by the taxing authorities based on the technical merits of the positions; otherwise, we establish reserves for uncertain tax positions.  We adjust reserves with respect to uncertain tax positions to address developments related to these positions, such as the closing of a tax audit, the expiration of a statute of limitations or the refinement of an estimate.  The provision for income taxes includes any reserves with respect to uncertain tax positions that are considered appropriate, as well as the related net interest and penalties. The Company has no uncertain tax positions as of December 31, 2016.2017.

 

The Company is no longer subject to income tax examinations for years before 2013. 

2014. 

 

Intangible assets – The Company’s intangible assets consist of trademarks, trade names, patents and royalty rights. The Company evaluates trademarks and trade names (all of which are indefinite-lived intangible assets) for impairment at least annually or when events or changes in circumstances indicate a potential impairment may exist. The Company evaluates royalty rights and patents (which are amortized on a straight-line basis over their useful lives) for impairment when events or changes in circumstances indicate an impairment may exist. No impairment was recorded in 2016 and 2015.    

2017 or 2016.    

 

Foreign currency adjustmentstranslationTranslation adjustments result from translatingAssets and liabilities of the Company’s Canadian subsidiary’s financial statements into U.S. dollars. The Company’ssubsidiary are translated from Canadian subsidiary’s functional currency is the Canadian dollar. Assets and liabilities are translateddollars to United States dollars at exchange rates in effect at the balance sheet date.  Income and expenses are translated at average exchange rates during the year. ResultingThe translation adjustments for the reporting period are included in our statements of comprehensive income, and the cumulative effect of these adjustments are includedreported in ourthe Company’s balance sheet as accumulated other comprehensive loss within Shareholders’ Equity.

 

Earnings per share The Company computes earnings per share in accordance with the provisions of ASC Topic 260, "Earnings Per Share," which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. Basic earnings per share are computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share are computed assuming the exercise of dilutive stock options under the treasury stock method and the related income tax effects.  See Note 14 - Earnings per share.

 

F-9

Note 2 – Inventories:

 

The composition of inventories at December 31, 20162017 and 20152016 are as follows:

 

 2016 2015  2017 2016 
Raw materials $3,633,641  $3,749,702  $3,994,624  $3,633,641 
Finished goods  5,235,207   4,445,130   5,354,097   5,235,207 
Inventories, gross  8,868,848   8,194,832   9,348,721   8,868,848 
                
Inventory reserves  (268,159)  (279,882)  (274,295)  (268,159)
                
Inventories, net $8,600,689  $7,914,950  $9,074,426  $8,600,689 

 

The inventory reserves shown in the table above reflect slow moving and obsolete inventory.

 

The Company operates a vendor managed inventory program with one of its customers to improve the promotion of the Company'sCompany’s products.  The Company manages the inventory levels at this customer’s warehouses and recognizes revenue as the products are sold by the customer. The inventories managed at the customer’s warehouses, which are included in inventories, net, amounted to approximately $551,000$494,000 and $543,000$551,000 at December 31, 20162017 and 2015,2016, respectively.

 

Note 3 – Property, plant and equipment:

 

The Company’s property, plant and equipment at December 31, 20162017 and 20152016 consisted of the following:

 

 Estimated      Estimated     
 Useful Life 2016  2015  Useful Life 2017 2016 
              
Land   $278,325  $278,325    $278,325  $278,325 
Building and Improvements 30 years  4,652,669   4,652,669  30 years  4,673,409   4,652,669 
Manufacturing and warehouse equipment 6-20 years  9,239,876   9,072,162  6-20 years  9,616,086   9,239,876 
Office equipment and furniture 3-5 years  1,344,732   1,293,609  3-5 years  1,367,244   1,344,732 
Construction in process    387,417   215,155 
Leasehold improvements 10-15 years  558,666   544,146  10-15 years  567,898   558,666 
Vehicles 3 years  10,020   42,283  3 years  10,020   10,020 
Construction in process    5,197,780   387,417 
Property, plant and equipment, gross    16,471,705   16,098,349     21,710,762   16,471,705 
                    
Less accumulated depreciation    (11,575,732)  (10,741,961)    (12,419,095)  (11,575,732)
                    
Property, plant and equipment, net   $4,895,973  $5,356,388    $9,291,667  $4,895,973 

Construction in progress at December 31, 2017 and 2016 includes $5,087,897 and $188,041, respectively, relating to the expansion of the manufacturing, warehouse and distribution facilities of the Company’s wholly-owned subsidiary, KINPAK Inc. (“Kinpak”), in Montgomery, Alabama. The Company estimates that the total cost of this expansion project will be approximately $6.0 million, and the project is expected to be completed and placed into service during 2018.

 

Note 4– Revolving line of credit:

 

On November 17, 2016,August 31, 2017, the Company and Regions Bank entered into a Business Loan Agreement (the “Business Loan Agreement”), under which the Company was provided a renewed revolving line of credit. Under the Business Loan Agreement, the Company may borrow up to the lesser of (i) $4 million$6,000,000 or (ii) a borrowing base equal to 85% of Eligible Accounts (as defined in the Business Loan Agreement: generally, accounts receivable from unaffiliated entities containing selling terms and conditions acceptable to Regions Bank, subject to specified exceptions)Agreement) plus 50% of Eligible Inventory (as defined in the Business Loan Agreement). Interest on amounts borrowed under the revolving line of credit is payable monthly at the 30 dayone month LIBOR rate plus 1.50%1.5% per annum, computed on a 365/360 basis. The interest rate will be increased an additional 2.0% if an event of default occurs.Eligible Accounts do not include, among other things, accounts receivable from affiliated entities.

 

Outstanding amounts under the revolving line of credit are payable on demand. If no demand is made, the Company may repay and reborrow funds from time to time until expiration of the revolving line of credit on August 31, 2017,2018, at which time all outstanding principal and interest will be due and payable. The Company’s obligations under the revolving line of credit are secured by, among other things, the Company’s accounts receivable and inventory and, as a result of cross-collateralization of the Company’s obligations under the term loan described in Note 6 and the revolving line of credit, real property and equipment at the Montgomery, Alabama facility of the Company’s subsidiary, Kinpak, Inc. ("Kinpak").The Business Loan Agreement includes financial covenants requiring that the Company maintain a minimum debt servicefixed charge coverage ratio (generally, EBITDAR (net operating profit plus depreciation, amortization and rent/lease expense) divided bythe ratio of (A) EBITDA for the most recently completed four fiscal quarters minus the sum of Company’s distributions to its shareholders, taxes paid and unfunded capital expenditures during such period to (B) current maturities of long-termCompany long term debt as of the end of the most recent fiscal quarter plus scheduled interest and lease rent expense)expense incurred over the most recently completed four fiscal quarters) of 1.751.20 to 1.00, calculated on a trailing twelve month basis,1, tested quarterly, and a maximum debt“debt to capitalizationcap” ratio (generally, funded debt divided by the sum of net worth and funded debt) of 0.75 to 1.00, calculated quarterly.1, as of the end of each fiscal quarter. For purposes of computing the fixed charge coverage ratio, “EBITDA” generally is defined as net income before taxes and depreciation expense plus amortization expense, plus interest expense, plus non-recurring and/or non-cash losses and expenses, minus non-recurring and/or non-cash gains and income; “unfunded capital expenditures’ generally is defined as ‘capital expenditures made from Company funds other than funds borrowed through term debt incurred to finance such capital expenditures; and ‘long term debt’ generally is defined as “debt instruments with a maturity principal due date of one year or more in length,” including, among other listed contractual debt instruments, “revolving lines of credit” and “capital leases obligations.” For the year ended December 31, 2016, our debt service2017, the Company’s fixed charge coverage ratio was approximately 10.607.30 to 1.00, and at December 31, 2016, our2017, the Company’s debt to capitalization ratio was approximately 0.020.15 to 1.00. The revolving line of credit is subject to several events of default, including a decline in the majority shareholder’s ownership below 50% of all outstanding shares. The Business Loan Agreement is a successor to earlier agreements under which Regions Bank provided a revolving line of credit to the Company in the maximum amount of $6 million. At December 31, 20162017 and December 31, 2015,2016, the Company had no borrowings under theits revolving line of credit thenin connection with the Business Loan Agreement and a predecessor agreement previously in effect.

F-10

 

Note 5– Accrued expenses payable:

 

Accrued expenses payable at December 31, 20162017 and 20152016 consisted of the following:

 

 2016 2015  2017 2016 
          
Accrued customer promotions $546,127  $491,378  $343,172  $546,127 
Accrued payroll, commissions, and benefits  287,376   269,380   280,783   287,376 
Other  266,416   337,963   188,107   266,416 
                
Total accrued expenses payable $1,099,919  $1,098,721  $812,062  $1,099,919 

 

Note 6– Long-term debt:

Industrial Development Bond Financing

On September 26, 2017, the Company’s wholly-owned subsidiary, KINPAK, Inc. (“Kinpak”) indirectly obtained a $4,500,000 loan from Regions Capital Advantage, Inc. (the “Lender”). The proceeds of the loan are being used principally to pay or reimburse costs of constructing an approximately 85,000 square foot addition to Kinpak’s manufacturing, warehouse and distribution facilities in Montgomery, Alabama, and costs of purchasing and installing associated machinery and equipment (the “Project”).

The loan was funded by the Lender’s purchase of a $4,500,000 industrial development bond (the “Bond”) issued by The Industrial Development Board of the City of Montgomery, Alabama (the “IDB”). The Bond is a limited obligation of the IDB and is payable solely out of revenues and receipts derived from the leasing or sale of Kinpak’s facilities. In this regard, Kinpak is obligated to fund the IDB’s payment obligations by providing rental payments under a lease between the IDB and Kinpak (the “Lease”), under which Kinpak leases its facilities from the IDB. Under the Lease, prior to the maturity date of the Bond, Kinpak may repurchase the facilities for $1,000 if the Bond has been redeemed or fully paid.

The Bond bears interest at the rate of 3.07% per annum, calculated on the basis of a 360-day year and the actual number of days elapsed (subject to increase to 6.07% per annum upon the occurrence of an event of default), and is payable in 118 monthly installments of $31,324 beginning on November 1, 2017 and ending on August 1, 2027, with a final principal and interest payment to be made on September 1, 2027 in the amount of $1,799,201. The Bond provides that the interest rate will be subject to adjustment if it is determined by the United States Treasury Department, the Internal Revenue Service, or a similar government entity that the interest on the Bond is includable in the gross income of the Lender for federal income tax purposes.

Under the Lease, Kinpak is required to make rental payments for the account of the IDB to the Lender in such amounts and at such times as are necessary to enable the payment of all principal and interest due on the Bond and other charges, if any, payable in respect of the Bond. The Lease also provides that Kinpak may redeem the Bond, in whole or in part, by prepaying its rental payment obligations in an amount sufficient to effect the redemption. In addition, the Lease contains provisions relating to the Project, including limitations on utilization of Bond proceeds, deposit of unused proceeds into a custodial account (as described below) and investment of monies held in the custodial account.

Payment of amounts due and payable under the Bond and other related agreements are guaranteed by the Company and its other consolidated subsidiaries. In connection with its guarantee, the Company is subject to certain covenants, including financial covenants that effectively are substantially the same as the financial covenants included in the Business Loan Agreement described in Note 4.

Through December 31, 2017, of the $4,500,000 proceeds of the Bond sale, approximately $1,699,000 has been applied to reimburse Kinpak for Project expenditures and approximately $54,000 was paid directly to other parties for certain transaction costs. The remaining amount is deposited into a custodial account and will be drawn by Kinpak from time to time to fund additional expenditures related to the Project. Because the Lease contains limitations on the manner in which the Kinpak may utilize funds held in the custodial account, such funds are classified as restricted cash on the Company’s balance sheet.

The Company incurred debt financing costs of $196,095 in connection with the financing. These costs are shown as a reduction of the debt balance and are being amortized under the effective interest method.

F-11

Other Long Term Obligations

 

On July 6, 2011, in connection with a credit agreement among the Company, Kinpak, Regions Bank and Regions Equipment Finance Corporation (“REFCO”), an Equipment Finance Addendum to thea previously outstanding credit agreement (the “Addendum”) was entered into by the Company, Kinpak and REFCO. Under the Addendum, REFCO provided to the Company a $2,430,000 term loan with a fixed interest rate of 3.54% per annum.   Principal and interest on the term loan are payable in equal monthly installments of $37,511 through July 6, 2017, the date the term loan matures.  In the event the Company’s debt service coverage ratio falls to or below 2.00 to 1.00, interest on the term loan will increase to 4.55% per annum. The proceeds of the term loan were used to pay Kinpak’s remaining obligations under a lease agreement relating to industrial revenue bonds used to fund thea previous expansion of Kinpak’s facilities and acquisition of related equipment. At December 31, 2016, approximately $260,000 was outstanding underThe term loan matured on July 6, 2017, and the term loan.Company paid all remaining principal and interest at maturity.

 

At December 31, 20162017 and 2015,2016, the Company was obligated under various capital lease agreements covering equipment utilized in the Company’s operations.  The capital leases, aggregating approximately $69,000$50,000 and $88,000$69,000 at December 31, 20162017 and December 31, 2015,2016, respectively, mature on July 1, 2020 and carry an interest rate of 2% per annum..

 

The following table provides information regarding the Company’s long-term debt at December 31, 20162017 and 2015:2016:

 

 Current Portion Long-term Portion  Current Portion Long Term Portion 
 2016 2015 2016 2015  December 31,
2017
 

December 31,

2016

 December 31,
2017
 December 31,
2016
 
         
Obligations related to industrial development bond financing $240,395  $---  $4,222,241  $--- 
Term loan $259,503  $432,601  $---  $259,503   ---   259,503   ---   --- 
Capitalized equipment leases  18,889   18,547   50,426   69,315   19,238   18,889   31,188   50,426 
                
Total long-term debt $278,392  $451,148  $50,426  $328,818 
Total principal of long term debt  259,633   278,392   4,253,429   50,426 
Debt issuance costs  (19,616)  ---   (171,636)  --- 
Total long term debt $240,017  $278,392  $4,081,793  $50,426 

 

Required principal payments under the Company’s term loan and capital lease obligations are set forth below:

 

Year ending December 31,      
2017 $278,392 
2018  19,238  $259,633 
2019  19,593   267,578 
2020  11,595   267,066 
2021  263,881 
2022  272,213 
Thereafter  3,182,691 
Total $328,818  $4,513,062 

 

Note 7 – Intangible Assets:

 

The Company’s intangible assets at December 31, 20162017 and 20152016 consisted of the following:

 

2016December 31, 2017 

 

Intangible Asset Cost  Accumulated
Amortization
  Net 
Intangible Assets Cost Accumulated
Amortization
 Net 
Patents $622,733  $335,300  $287,433  $622,733  $387,636  $235,097 
Trade names and trademarks  

1,131,125

   

549,561

   581,564   1,131,125   549,561   581,564 
Royalty rights  160,000   61,309   98,691   160,000   79,253   80,747 
Total intangible assets $

1,913,858

  $

946,170

  $967,688  $1,913,858  $1.016,450  $897,408 

 

2015December 31, 2016 

 

Intangible Asset Cost Accumulated
Amortization
 Net 
Intangible Assets Cost Accumulated
Amortization
 Net 
Patents $622,733  $282,964  $339,769  $622,733  $335,300  $287,433 
Trade names and trademarks  

1,131,125

   

549,561

   581,564   1,131,125   549,561   581,564 
Royalty rights  160,000   43,365   116,635   160,000   61,309   98,691 
Total intangible assets $

1,913,858

  $

875,890

  $1,037,968  $1,913,858  $946,170  $967,688 

 

F-12

At December 31, 2017 and 2016, and 2015, the tradenamestrade names and trademarks are considered indefinite-lived (the Star brite® trade name and trademark initially was deemed to have an estimated useful life of 40 years until, pursuant to Statement of Financial Accounting Standards No. 142 (currently codified in ASC Topic 350, “Intangibles-Goodwill and Other”), the Company determined that, effective January 1, 2002, the assets had indefinite lives).indefinite-lived. The patents (the most significant of which (the “ClO2“ClO2 Patents”) relate to a device for producing chlorine dioxide (ClO2)(ClO2) that is incorporated into the Company’s disinfectant, sanitizer and deodorizing products)deodorizer products) had a carrying value, net of amortization, of $287,433$235,097 at December 31, 20162017 (of which $282,963$231,515 is attributable to the ClO2ClO2 Patents). The ClO2ClO2 Patents expire in 2022 and the other patents expire in 2021. The royalty rights (which the Company purchased from an unaffiliated entity that previously owned the ClO2ClO2 Patents and retained the royalty rights after selling the patents) expire in December 2021 and are amortized on a straight line basis over their remaining useful lives.

 

Amortization expense related to intangible assets was $70,280 ($52,336 attributable to the patents and $17,944 attributable to the royalty rights) for each of the yearyears ended December 31, 20162017 and approximately $69,392 ($51,448 attributable to the patents and $17,944 attributable to the royalty rights) for the year ended December 31, 2015.2016. 

 

Note 8– Income taxes:

 

The components of the Company’s consolidated provision (benefit) for income taxes are as follows:

 

 2016 2015  2017 2016 
Federal – current $982,298  $136,479  $1,101,503  $982,298 
Federal – deferred  (25,565)  101,290   (60,364)  (25,565)
State – current  27,163   1,842   31,930   27,163 
State – deferred  (745)  3,065   892   (745)
Total provision for income taxes $983,151  $242,676  $1,073,961  $983,151 

 

The reconciliation of the provision for income taxes at the statutory rate to the reported provision for income taxes is as follows:

 

 2016 % 2015 %  2017 % 2016 % 
Income Tax computed at statutory rate $1,046,629   34.0% $239,146   34.0% $1,250,348   34.0% $1,046,629   34.0%
State tax, net of federal benefit  17,916   0.6%  889   0.1%  21,074   0.6%  17,916   0.6%
Share based compensation  (2,013)  (0.1)%  (2,881)  (0.4)%  (6,303)  (0.2)%  (2,013)  (0.1)%
Domestic production activities deduction  (97,645)  (3.2)%  (13,905)  (1.9)  (110,410)  (3.0)%  (97,645)  (3.2)%
Other, permanent adjustments  23,991   0.8%  19,984   2.8%
Tax credits and prior year tax adj.  (5,727)  (0.2)%  (557)  (0.1)%
Effect of tax rate change on deferred taxes  (90,980)  (2.5)%  ---   0.0%
Permanent adjustments  24,202   0.7%  23,991   0.8%
Tax credits and other  (13,970)  (0.4)%  (5,727)  (0.2)%
Provision for income taxes $983,151   31.9% $242,676   34.5% $1,073,961   29.2% $983,151   31.9%

 

The Company’s deferred tax asset (liability) consisted of the following at December 31, 20162017 and 2015:2016:

 

 2016 2015  2017 2016
Deferred tax Asset (liability)        
Deferred tax asset (liability)    
Inventory reserves $93,829  $97,931  $68,631  $93,829 
Trade accounts receivable allowances  26,259   27,404   9,017   26,259 
Net Operating loss carryforward state  303,784   361,488   366,176   303,784 
Depreciation of property and equipment  (333,455)  (365,012)  (231,543)  (333,455)
Net deferred tax asset  90,417   121,811   239,549   90,417 
Valuation allowance  (303,784)  (361,488)  (366,176)  (303,784)
Total net deferred tax (liability) $(213,367) $(239,677) $(153,895) $(213,367)

The Tax Cuts and Jobs Act was enacted on December 22, 2017. The legislation significantly changes United States tax law by, among other things, reducing our corporate income tax rates from 34% to 21%, effective January 1, 2018. As a result of the reduction in the corporate income tax rate, the Company revalued its net deferred tax liabilities at December 31, 2017 and recognized a $90,980 tax benefit in the Company’s consolidated statement of operations

At December 31, 20162017 and 2015,2016, the Company has a net operating loss carryforward with the state of Alabama. The net operating losses of $4,676,600$5,636,482 and $5,561,354$4,676,600 expire between 2020 and 2023.2031. The Company does not expect to be able to utilize these losses and has recorded a valuation allowance for the full amount of the net operating losses.

Note 9– Related party transactions:

 

During 2016,2017, as in previous years, the Company sold products to companies affiliated with Peter G. Dornau, who is itsthe Company’s Chairman, President and Chief Executive Officer. The affiliated companies distribute the products outside of the United States and Canada. The Company also provides administrative services to these companies. Sales to the affiliated companies aggregated approximately $1,850,000$2,070,000 and $2,075,000$1,850,000 during the years ended December 31, 20162017 and 2015,2016, respectively, and fees for administrative feesservices aggregated approximately $621,000$884,000 and $527,000$735,000 (including approximately $120,000 and $115,000 to reimburse the Company for business related expenditures that it made on behalf of the affiliated companies) during the years ended December 31, 20162017 and 2015,2016, respectively.  The Company had accounts receivable from the affiliated companies in connection with the product sales and administrative services aggregating approximately $1,190,000$1,584,000 and $1,051,000$1,190,000 at December 31, 2017 and 2016, and 2015, respectively.

 

F-13

An entity that is owned by Peter G. Dornau, the Company’s Chairman, President and Chief Executive Officer provides several services to the Company.  Under this arrangement, the Company paid the entity $42,000 for research and development services infor each of the years ended December 31, 20162017 and 2015.2016. The research and development expenses are included in our statementthe Company’s statements of operations for the years ended December 31, 2017 and 2016 as a selling and administrative expense. In addition, during the year ended December 31, 2017, the Company paid this entity $64,250 for providing charter boat services for marketing events for the Company’s nonaffiliated customers. The charter boat services are included in the Company’s statement of operations for the year ended December 31, 2017 as an advertising and promotion expense. During the year ended December 31, 2016, the Company paid this entity $25,000 for the production of television commercials and $9,000 for providing charter boat services for entertainment of Companythe Company’s nonaffiliated customers. These amounts are included in our 2016 statement of operations as an advertising and promotion expense.

 

The Company leases office and warehouse facilities in Fort Lauderdale, Florida from an entity controlled by its Chairman, President and Chief Executive Officer.    See Note 10 for a description of the lease terms.

 

A director of the Company is Regional Executive Vice President of an entity frominsurance broker through which the Company sourceshas sourced most of its commercialgeneral and liability insurance needs.  Theand, commencing in 2017, its health insurance.  During the years ended December 31, 2017 and 2016, the Company paid an aggregate of approximately $1,235,000 and $697,000, and $925,000 torespectively, in insurance premiums on policies obtained through the entity during the years ended December 31, 2016 and 2015, respectively.insurance broker.

 

Note 10– Commitments and contingencies:

 

The Company leases its executive offices and warehouse facilities in Fort Lauderdale, Florida from an entity controlled by its Chairman, President and Chief Executive Officer. The lease, as extended, expires on December 31, 2023. The lease requires an annual minimum base rent of $94,800 and provides for a maximum annual 2% increase in subsequent years, although the entity has not raised the minimum rent since the Company entered into a previous lease agreement in 1998. Additionally, the leasing entity is entitled to reimbursement of all taxes, assessments, and any other expenses that arise from ownership. Each of the parties to the lease has agreed to review the terms of the lease every three years at the request of the other party.  Rent expense under the lease was approximately $97,000 and $98,000 for each of the years ended December 31, 20162017 and 2015, respectively.2016.  The rent expense is included in our statementthe Company’s statements of operations as a selling and administrative expense.

 

The Company also leases a 15,000 square foot warehouse from an unrelated third party in Montgomery, ALAlabama near its Kinpak manufacturing facility for the purpose of fabricating and assembling brushes used for cleaning boats, automobiles and recreational vehicles. The lease commenced on August 1, 2016 and expires on July 31, 2018. The lease requiresCompany pays monthly rent paid in advance of $4,375.$4,375 under the lease.

 

The following is a schedule of minimum future rentals on the Company’s non-cancelable operating leases.

 

12 month period ending December 31,
2017 $148,564 

Year ending December 31,

Year ending December 31,

2018 128,610  $126,689 
2019 99,945   97,985 
2020 101,944   99,945 
2021 103,983   101,944 
2022  103,983 
Thereafter  214,246   106,062 
Total $797,292  $636,608 

  

Note 11 - Stock options and awards:

 

On May 29, 2015, the Company’s shareholders approved the Ocean Bio-Chem, Inc. 2015 Equity Compensation Plan (the “Plan”). The Plan provides for grants of several types of awards at the discretion of the Equity Grant Committee of the Company’s Board of Directors, including stock options, stock units, stock awards, stock appreciation rights and other stock based awards. The Plan authorizes the issuance of 630,000 shares of Company common stock, subject to anti-dilution adjustments upon the occurrence of certain events affecting the common stock.stock During the years ended December 31, 20162017 and 2015,2016, the Company issued stock awards under the Plan respectively aggregating 142,00079,100 and 65,500142,000 shares of common stock, respectively, to officers, key employees, directors and a consultant of an affiliated company. Following the withholding of an aggregate of 3,9185,500 and 4,2443,918 shares of common stock, respectively, in connection with a net exercise feature of the Plan, 138,08273,600 and 61,256138,082 shares were delivered to the award recipients, for the years ended December 31, 20162017 and 2015,2016, respectively. At December 31, 2016, 422,5002017, 343,400 shares remained available for future issuance under the Plan.  The shares vested immediately upon issuance and were fully expensed in the period in which they were awarded. Compensation expense related to the stock awards was $305,780$324,145 and $168,663$305,780 for the years ended December 31, 20162017 and 2015,2016, respectively. The companyCompany withheld shares pursuant to net share settlements, within 2017 and 2016 that had a value of $8,424$22,468 and $12,610$8,424, respectively, for income tax withholding related to the awards. As a result of the adoption of the Plan, no further stock awards will be made under the Company’s equity compensation plans previously approved by its shareholders (the “Prior Plans”).

F-14

 

Prior to the May 29, 2015 effective date of the Plan, stock options were granted under the Prior Plans. Only non-qualified options granted under the Prior Plans were outstanding on December 31, 2016.2017. Outstanding non-qualified options were granted to outside directors, have a 10-year term from the date of grant and are immediately exercisable.  The last tranche of non-qualified options previously granted terminate on April 25, 2020.  There was no compensation expense attributable to stock options recognized during the years ended December 31, 20162017 and 2015,2016, and at December 31, 20162017 and 2015,2016, there was no unrecognized compensation cost related to share based compensation arrangements

During 2017, stock options to purchase an aggregate of 40,000 shares were exercised. The Company received a total of $26,400, withheld 5,957 shares in connection with the net exercise feature of the stock options and delivered an aggregate of 34,043 shares to the option holders who exercised their options.

 

During 2016, stock options to purchase an aggregate of 30,000 shares were exercised. The Company received a total of $21,600, withheld 4,519 shares in connection with the net exercise feature of the stock options and delivered an aggregate of 25,481 shares to the option holders who exercised their options.

 

During 2015, a former director exercised stock options to purchase 10,000 shares. Following the withholding of 2,156 shares in connection with the net exercise feature of the stock options, the Company delivered 7,844 shares to the former director.

The following tables provide information at December 31, 2016 and 2015 regarding outstanding options under the Company’s stock option plans.plans at December 31, 2017 and 2016.  As used in the table below, “2002 NQ” refers to the Company’s 2002 Non-Qualified Stock Option Plan and “2008 NQ” refers to the Company’s 2008 Non-Qualified Stock Option Plan.

 

At December 31, 2016:         
At December 31, 2017:At December 31, 2017:         
Plan Date
Granted
 Options Outstanding Exercisable
Options
 Exercise Price Expiration
Date
 Weighted Average
Remaining  Life
  Date
Granted
 Options Outstanding Exercisable
Options
 Exercise Price Expiration
Date
 Weighted Average
Remaining  Life
 
2002 NQ 12/17/07  40,000   40,000   1.32  12/16/17  1.0 
2008 NQ 1/11/09  40,000   40,000   0.69  1/10/19  2.1  1/11/09  40,000   40,000   0.69  1/10/19  1.0 
2008 NQ 4/26/10  20,000   20,000   2.07  4/25/20  3.4  4/26/10  20,000   20,000   2.07  4/25/20  2.4 
  100,000   100,000  $1.22   1.9   60,000   60,000  $1.15   1.5 

 

At December 31, 2015:         
At December 31, 2016:At December 31, 2016:         
Plan Date
Granted
 Options Outstanding Exercisable
Options
 Exercise Price Expiration
Date
 Weighted Average
Remaining  Life
  Date
Granted
 Options Outstanding Exercisable
Options
 Exercise Price Expiration
Date
 Weighted Average
Remaining  Life
 
2002 NQ 4/3/06  30,000   30,000  $1.08  4/2/16  0.3 
2002 NQ 12/17/07  40,000   40,000   1.32  12/16/17  2.0  12/17/07  40,000   40,000   1.32  12/16/17  1.0 
2008 NQ 1/11/09  40,000   40,000   0.69  1/10/19  3.1  1/11/09  40,000   40,000   0.69  1/10/19  2.1 
2008 NQ 4/26/10  20,000   20,000   2.07  4/25/20  4.4  4/26/10  20,000   20,000   2.07  4/25/20  3.4 
  130,000   130,000  $1.19   2.3   100,000   100,000  $1.22   1.9 

 

The following table provides information relating to stock option transactions during the years ended December 31, 20162017 and 2015:2016:

 

 2016 2015  2017 2016 
   Weighted   Weighted    Weighted   Weighted 
   Average   Average    Average   Average 
   Exercise   Exercise    Exercise   Exercise 
 Shares Price Shares Price  Shares Price Shares Price 
Options outstanding beginning of the year  130,000  $1.19   140,000  $1.18   100,000  $1.22   130,000  $1.19 
Options exercised  (30,000)  1.08   (10,000)  1.08   (40,000)  1.32   (30,000)  1.08 
Total  100,000  $1.22   130,000  $1.19   60,000  $1.15   100,000  $1.22 

F-15

 

Note 12 – Major customers:

 

The Company had net sales to each of two major customers that constituted in excess of 10% of the Company’s consolidated net sales for each of the years ended December 31, 20162017 and 2015.2016.  Net sales to each of these two customers aggregatedrepresented approximately 33.0%22.4% and 38.2%11.6% of consolidated net sales for 20162017 and 2015,approximately 20.3% and 12.7% of consolidated net sales for 2016, respectively.

 

Note 13 – Litigation expense:

 

During the yearsyear ended December 31, 2015 and 2016, the Company was engaged in litigation with a competitor in which each of the Company and the competitor claimed that the other was engaged in false advertising and related violations of law. Following a trial in which it was determined that neither party was liable to the other, the matter was concluded. The Company incurred professional fees and expenses relating to this matter of $1,146,000 and $1,174,000 during the yearsyear ended December 31, 2016. This amount is included in the Company’s statement of operations for the year ended December 31, 2016 and 2015, respectively. These amounts are included inas selling and administrative expenses. The matter concluded in 2016, and no expenses related to this litigation were incurred during the year ended December 31, 2017. 

 

Note 14 – Earnings per share:

 

Basic earnings per share are calculated by dividing net income by the weighted average number of shares outstanding during the reporting period.  Diluted earnings per share reflect additional dilution from potential common stock issuable upon the exercise of outstanding stock options.  The following table sets forth the computation of basic and diluted earnings per common share, as well as a reconciliation of the weighted average number of common shares outstanding to the weighted average number of shares outstanding on a diluted basis.

 

  Years Ended
December 31,
 
  2016  2015 
Earnings per common share –Basic      
       
Net income $2,095,171  $460,694 
         
Weighted average number of common shares outstanding  9,059,966   8,940,593 
         
Earnings per common share – Basic $0.23  $0.05 
         
Earnings per common share – Diluted        
         
Net income $2,095,171  $460,694 
         
Weighted average number of common shares outstanding  9,059,966   8,940,593 
         
Dilutive effect of employee stock-based awards  56,550   86,513 
         
Weighted average number of common shares outstanding - assuming dilution  9,116,516   9,027,106 
         
Earnings per common share - Diluted $0.23  $0.05 

  Years Ended
December 31,
 
  2017  2016 
Earnings per common share –Basic      
       
Net income $2,603,534  $2,095,171 
         
Weighted average number of common shares outstanding  9,190,429   9,059,966 
         
Earnings per common share – Basic $0.28  $0.23 
         
Earnings per common share – Diluted        
         
Net income $2,603,534  $2,095,171 
         
Weighted average number of common shares outstanding  9,190,429   9,059,966 
         
Dilutive effect of employee stock-based awards  63,373   56,550 
Weighted average number of common shares outstanding - assuming dilution  9,253,802   9,116,516 
         
Earnings per common share - Diluted $0.28  $0.23 

 

The Company had no stock options outstanding at December 31, 20162017 and 2015,2016, respectively that were anti-dilutive and therefore not included in the diluted earnings per common share calculation.

 

Note 15Special Cash Dividend:Dividends:

 

On April 26, 2016,13, 2017, the Company paidCompany’s Board of Directors declared a special cash dividend of $0.06 per common share payable on May 11, 2017 to all shareholders of record on April 27, 2017.  On April 27, 2017, there were 9,154,243 shares of common stock outstanding;  therefore, dividends aggregating $549,255 were paid on May 11, 2017.

On March 25, 2016, the Company’s Board of Directors declared a special cash dividend of $0.06 per common share payable on April 26, 2016 to all shareholders of record on April 12, 2016.  The dividend aggregated $540,531.   On April 12, 2016, there were 9,008,855 shares of common stock outstanding; therefore, dividends aggregating $540,531 were paid on April 26, 2016.

F-16

 

Note -16 – Recent Accounting Pronouncements:

 

Accounting Guidance Adopted by the Company

In NovemberJuly 2015, the Financial Accounting Standards Board FASB(“FASB”) issued ASU 2015-17, “Income TaxesAccounting Standards Update (“ASU”) No. 2015-11, “Inventory” (Topic 740): Balance Sheet Classification of Deferred Taxes.” The guidance under ASU 2015-17 is designed330) to simplify the presentationmeasurement of deferred tax assetsinventory subsequent to its initial measurement and liabilities withinto more closely align the balance sheet by requiring generally that all deferred tax assets and liabilities be classified as non-current. Under previously applicable guidance, an entity was required to separate deferred tax liabilities and assets into a current amount and a noncurrent amount.measurement of inventory under GAAP with the measurement of inventory under International Financial Reporting Standards. The guidance in ASU 2015-11 (which applies to inventory that is effective for years beginning after December 15, 2016 with early adoption permitted,measured using the first-in, first-out (FIFO) or average cost method, but not to inventory measured using the last-in, first-out (LIFO) or the retail inventory method), requires subsequent measurement of inventory to be at the lower of cost and can be applied prospectivelynet realizable value (rather than the lower of cost or retrospectively.market, as under previous guidance).  Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.   The Company adopted this guidance in the quarter ended September 30, 2016, retrospectively toeffective January 1, 2016. As2017. The adoption of this guidance did not have a result ofmaterial impact on the adoption, we made the following reclassifications to the 2015 consolidated balance sheet: a $125,335 decrease to current deferred tax asset and a $125,335 decrease to noncurrent deferred tax liability.Company’s financial statements. 

Accounting Guidance Not Yet Adopted by the Company

 

In May 2014, the FASB issued Accounting Standards Update (“ASU”)ASU 2014-09, "Revenue from Contracts with Customers (Topic 606)". ASU 2014-19,2014-09, which has been modified on several occasions, provides new guidance designed to enhance the comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets. The core principle of the new guidance is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The new guidance also requires disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The new guidance is effective for annual periodsus beginning after December 15, 2017January 1, 2018. The Company will use the full retrospective method. Management has evaluated our current revenue recognition process and interim periods within those years; early applicationreviewed active customer agreements and assessed that under ASU 2014-09 our performance obligation to our customers is permitted for annual periods beginning after December 15, 2016. We do not expect this new standardsatisfied when the goods are shipped and title of the goods is transferred, or in the case in which our inventory is held in consignment upon sale to have a material impact onthird party, when we are notified of sales by the amount andconsignee.   The timing of our revenue recognition.recognition will not change, however certain allowances given to customers primarily cooperative advertising will be considered a reduction of revenue instead of an advertising and promotion expense. This reclassification will not affect net income.

In February 2016, the FASB issued Accounting Standards Update No. 2016-02 (“ASU 2016-02”), “Leases.” Generally, under ASU 2016-02, “Leases (Topic 842).” The principal change under this new accounting guidance is that lessees under leases classified as operating leases generally will be required to recognize, at the commencement date of each lease having a right-of-use asset andterm of more than 12 months, both a lease liability, onwhich is a lessee’s obligation to make lease payments arising from a lease, initially measured at the balance sheet. Currentpresent value of the lease accounting standards do not require lesseespayments, and a right-to-use asset, which is an asset that represents the lessee’s right to recognize assetsuse or control the use of the underlying asset for the lease term. Leases will be classified as either finance or operating; the classification will affect the manner of reporting expenses and liabilities arising under operating leases on the balance sheet.cash flows. The new guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early2018, with early adoption is permitted. The new standardguidance must be adopted using a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements; thestatements. The guidance provides certain practical expedients. The Company is currently evaluating this guidance to determine its impact on the Company’s financial statements.

 

In November 2016, the FASB issued ASU 2016-18, which requires entities to present the changes in total cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. The new guidance also requires a reconciliation of the totals in the statement of cash flows to the related captions in the balance sheet if restricted cash and restricted cash equivalents are presented in a different line item in the balance sheet. The amendments of this Update, which should be applied using a retrospective transition method to each period presented, are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early adoption is permitted. The adoption of this standard will change the presentation in the consolidated statements of cash flows.

In July 2015,January 2017, the FASB issued ASU No. 2015-11, “Inventory” (Topic 330)2017-04, Intangibles-Goodwill and Other, which simplifies the accounting for goodwill impairments by eliminating step 2 from the goodwill impairment test. Instead, if “the carrying amount of a reporting unit exceeds its fair value, an impairment loss shall be recognized in an amount equal to simplifythat excess, limited to the measurementtotal amount of inventory subsequentgoodwill allocated to its initial measurement and to more closely align the measurement of inventory under GAAP with the measurement of inventory under International Financial Reporting Standards.that reporting unit.” The guidance in ASU 2015-11 (which applies to inventory that is measured using the first-in, first-out (FIFO) or average cost method, but not to inventory measured using the last-in, first-out (LIFO) or the retail inventory method), requires subsequent measurement of inventory to be at the lower of cost and net realizable value (rather than the lower of cost or market, as under current guidance).  Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.  The amendments are effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this new standard will have on its consolidated financial statements.

In June 2016, the FASB issued ASU 2016-13 Financial Instruments – Credit Losses which replaces the incurred loss model with a current expected credit loss (“CECL”) model. The CECL model applies to financial assets subject to credit losses and measured at amortized cost and certain off-balance sheet exposures. Under current U.S. GAAP, an entity reflects credit losses on financial assets measured on an amortized cost basis only when losses are probable and have been incurred, generally considering only past events and current conditions in making these determinations. ASU 2016-13 prospectively replaces this approach with a forward-looking methodology that reflects the expected credit losses over the lives of financial assets, starting when such assets are first acquired. Under the revised methodology, credit losses will be measured based on past events, current conditions and reasonable and supportable forecasts that affect the collectability of financial assets. ASU 2016-13 also revises the approach to recognizing credit losses for available-for-sale securities by replacing the direct write-down approach with the allowance approach and limiting the allowance to the amount at which the security’s fair value is less than the amortized cost. In addition, ASU 2016-13 provides that the initial allowance for credit losses on purchased credit impaired financial assets will be recorded as an increase to the purchase price, with subsequent changes to the allowance recorded as a credit loss expense. ASU 2016-13 also expands disclosure requirements regarding an entity’s assumptions, models and methods for estimating the allowance for credit losses. The amendments of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The amendments should be applied prospectively with earlier application2019. Early adoption is permitted as of the beginning of an interim or annual reporting period.January 1, 2019. The Company does not expectis currently evaluating the impact the adoption toof this new standard will have a material impact on its consolidated financial statements.statements.  

Note -17 – Subsequent Event:

 

EXHIBIT INDEXOn March 19, 2018, the Company’s Board of Directors declared a special cash dividend of $0.06 per common share payable on April 16, 2018 to all shareholders of record on April 2, 2018. At the time of the filing of this report there were 9,254,580 shares of common stock outstanding; therefore, dividends aggregating $555,275 will be paid on April 16, 2018.

  

F-17

EXHIBIT INDEX

Unless otherwise noted, the file number of each referenced filing is 0-11102

 

Exhibit No. 
3.1.1Articles of Incorporation and amendments through May 20, 1994 (incorporated by reference to Exhibit 3.1 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2010).
3.1.2Articles of Amendment to the Articles of Incorporation, as filed on June 13, 2012 (incorporated by reference to Exhibit 3.1.2 to the Company's Annual Report on Form 10-K for the year ended December 31, 2012).
3.2   Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on December 5, 2011).
*10.110.1.1Business Loan Agreement, dated November 17, 2016,August 31, 2017, between the Company and Regions Bank (the “Business Loan Agreement”) (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017).
*10.210.1.2Promissory Note, dated November 17, 2016,August 31, 2017, issued by the Company to Regions Bank in connection with the revolving line of credit under the Business Loan Agreement (the “Promissory Note”) (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017).
*10.310.1.3Letter, dated November 17, 2016,August 31, 2017, from Regions Bank to the Company, regarding certain terms under the Business Loan Agreement and the Promissory Note.Note (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017).
10.4*10.1.4Letter, dated December 20, 2017, from Regions Bank to the Company, regarding certain terms of the Business Loan Agreement.
10.2Ocean Bio-Chem, Inc. 2015 Equity Compensation Plan, as amended (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 12, 2016).
10.510.3.1Credit Agreement, dated July 6, 2011, among the Company, Kinpak,Form of Industrial Development Revenue Bond (Kinpak Inc. and Regions Bank (the “Credit Agreement”)Project) Series 2017 (incorporated by reference to Exhibit 10.299.1 to the Company’s QuarterlyCurrent Report on Form 10-Q for8-K, filed with the quarter ended September 30, 2011)Securities and Exchange Commission on October 2, 2017).
10.610.3.2Equipment Finance Addendum,Second Restated Lease Agreement, dated July 6, 2011, amongas of September 1, 2017, between The Industrial Development Board of the Company, Kinpak,City of Montgomery and KINPAK, Inc. and Regions Equipment Finance Corporation (incorporated by reference to Exhibit 10.199.2 to the Company’s QuarterlyCurrent Report on Form 10-Q for8-K, filed with the quarter ended September 30, 2011)Securities and Exchange Commission on October 2, 2017).
10.710.3.3Promissory Note,

Mortgage, Security Agreement and Assignment of Rents and Leases, dated July 6, 2011, issuedas of September 1, 2017, provided by The Industrial Development Board of the CompanyCity of Montgomery and Kinpak,KINPAK, Inc. (incorporated by reference to Regions Equipment Finance Corporation in connectionExhibit 99.3 to the Company’s Current Report on Form 8-K, filed with the term loan under the CreditSecurities and Exchange Commission on October 2, 2017).

10.3.4Guaranty Agreement, dated as of September 1, 2017, provided by Ocean Bio-Chem, Inc. and its consolidated subsidiaries party thereto  (incorporated by reference to Exhibit 99.4 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 12, 2011)October 2, 2017).
10.8 10.4Ocean Bio-Chem, Inc. 2002 Non-Qualified Stock Option Plan, as amended (incorporated by reference to Exhibit 99.2 to the Company’s Registration Statement on Form S-8 (File No. 333-176268), filed with the Securities and Exchange Commission on August 12, 2011).
10.9 10.5Ocean Bio-Chem, Inc. 2008 Non-Qualified Stock Option Plan, as amended (incorporated by reference to Exhibit 99.5 to the Company’s Registration Statement on Form S-8(FileS-8 (File No. 333-176268), filed with the Securities and Exchange Commission on August 12, 2011).
10.1010.6.1

Net Lease, dated May 1, 1998, between Star Brite Distributing, Inc. and PEJE, IncInc. (incorporated by reference to Exhibit 10.14 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2004).

10.1110.6.2Renewal of Lease, dated May 1, 2008, between Star Brite Distributing, Inc. and PEJE, Inc. (incorporated by reference to Exhibit 10.24 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2008).
10.1210.6.3Amendment Number Two to Net Lease, dated May 16, 2013, between Star Brite Distributing, Inc. and PEJE, Inc. (incorporated by reference to Exhibit 10.13 to the Company's Annual Report on Form 10-K for the year ended December 31, 2013).
*21   List of Subsidiaries
*23.123Consent of Goldstein Schechter Koch, P.A. Independent Registered Public Accounting Firm.EisnerAmper LLP
*31.1Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act.
*31.2Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act.
*32.1Certification of Chief Executive Officer pursuant to Rule 13a-14(b) under the Securities Exchange Act and 18 U.S.C. Section 1350.
*32.2Certification of Chief Financial Officer pursuant to Rule 13a-14(b) under the Securities Exchange Act and 18 U.S.C. Section 1350.
101

The following materials from Ocean Bio-Chem Inc.’s Annual Report on Form 10-K for the year ended December 31, 2016,2017, formatted in XBLR (eXtensible Business Reporting Language):  (i) Consolidated Balance Sheets at December 31, 20162017 and December 31, 2015;2016; (ii) Consolidated Statements of Operations for the years ended December 31, 20162017 and 2015;2016; (iii) Consolidated Statements of Comprehensive Income for the years ended December 31, 20162017 and 2015;2016; (iv) Consolidated Statements of Changes in Shareholders Equity for the years ended December 31, 20162017 and 2015,2016, (v) Consolidated Statements of Cash Flows for the years ended December 31, 20162017 and 20152016 and (vi) Notes to Consolidated Financial Statements.

 

*     Filed herewith

herewith.

 

E-1